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Summary 
Introduction 
Health Problem 
In the scope of this assessment, vertebral metastases are the condition of in-
terest. 
Many tumour patients develop painful vertebral metastases in the course of 
their disease that destroy the vertebrae. These metastases represent the most 
common cause of chronic pain, fractures, reduced mobility and spinal cord 
compression [1, 2]. Therefore, patients with untreated painful vertebral metas-
tases may suffer from several complications, e.g., fractures, decreased health-
related quality of life (HRQoL), decreased mobility, and a reduced perfor-
mance status. Consequently, it can have negative effects on the functional 
capacity and can lead to depression and anxiety states [2-4]. The treatment 
of metastatic spinal lesions is usually palliative [5]. 
Description of Technology 
Radiofrequency ablation (RFA) is an image-guided minimally invasive ther-
mal ablation procedure for solid tumours [6, 7]. RFA for metastatic spinal 
lesions is performed using a transpedicular or parapedicular approach. Dur-
ing the procedure, the patient is positioned face down and sedated using con-
scious sedation or general anaesthesia [1, 8]. 
RFA uses imaging guidance to manually insert a needle electrode into the tu-
mour tissue. To access the metastasis in the vertebral body a cannula and a 
navigable probe is used. Via a radiofrequency generator high frequency alter-
nating current pulses are emitted into the tumour tissue [1, 9, 10]. The heat 
field generated by radiofrequency energy (50-90°C) causes the destruction of 
the malignant tissue and creates a cavity in the vertebral body [3]. These fea-
tures allow the safe destruction of vertebral metastases near heat-sensitive 
structures such as the spinal cord [1, 11]. 
If the vertebral body implies a risk of fracture after RFA an additional pre-
ventive treatment with vertebroplasty (cementation of the vertebral body) can 
be performed [12]. 
Research question 
Is radiofrequency ablation with/without vertebroplasty (or other add-on ther-
apies) in comparison to the standard of care (SoC) or no treatment in pa-
tients with metastatic spinal lesions more effective and safe concerning pain, 
functional status, HRQoL and complications? 
 
Methods 
To answer the research questions on efficacy and safety-related outcomes, a 
systematic literature search in five databases was conducted. In addition, we 
performed a hand search and screened information provided by the manu-
facturer and the submitting hospital to identify further relevant studies. The 
study selection, data extraction, and assessing the methodological quality of 
the studies was performed by two independent researchers. 
focus: metastases  
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patients develop painful 
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Domain effectiveness 
The following efficacy-related outcomes were used as evidence to derive a 
recommendation: pain relief, functional status and HRQoL. 
Domain safety 
The following safety-related outcomes were used as evidence to derive a rec-
ommendation: major complications and adverse events (procedure-related and 
not procedure-related). 
 
Results 
Available evidence 
A total of 4 prospective and 5 retrospective single-arm studies were eligible 
for inclusion in the current report. A cut-off of more than 30 patients was de-
fined as an inclusion criterion for retrospective studies. 
Overall, data on safety and efficacy was evaluated in 471 and 112 patients, 
respectively. 
Clinical effectiveness 
To assess the effectiveness of radiofrequency ablation for metastatic spinal 
lesions we could not identify any comparative studies. The only studies that 
met our inclusion criteria were four prospective single arm, partly multicen-
tre, studies with a total of 112 patients assessing the effectiveness of radiof-
requency ablation combined with vertebroplasty. 
Three prospective studies reported overall significant outcomes on pain re-
lief after treatment with RFA and vertebroplasty. Two studies assessed out-
comes on HRQoL with significant improvements throughout the follow-up 
periods. One study recorded no recurrence of vertebral metastases during the 
follow-up. 
Since none of the studies included a control group, they could not provide 
any serious information on a possible survival prolongation. 
Safety 
In the absence of data from controlled studies, no comparisons can be made 
for the safety assessment of RFA. Overall, safety outcomes were evaluated in 4 
prospective studies (112 patients) and in 5 retrospective studies (471 patients). 
None of the included studies reported major complications for the use of RFA. 
Overall, adverse events (procedure-related or not procedure-related) occurred 
in 105 patients who completed the follow-up, out of 583 included patients 
across the studies (18%). 
The most frequent procedure-related adverse events were increased pain and 
numbness (7.8%, 6/77 patients). The most frequent adverse event reported, 
which is not RFA-related, but vertebroplasty-related, was cement extravasa-
tion (18.7%, 67/358 patients). 
 
 
crucial outcomes  
for efficacy … 
… and safety 
4 prospective and  
5 retrospective  
single-arm studies 
4 prospective single-arm 
studies with 112 patients 
pain relief in 3 studies 
 
improvement in  
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adverse events occurred 
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 vertebroplasty-related: 
cement extravasation 
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Upcoming evidence 
Currently, there are three ongoing studies. One registry of the STAR® tumour 
ablation system (NCT02419703), one ongoing study on the combination of 
RFA and vertebroplasty (ChiCTR-INR-16010135) and one ongoing phase II 
study evaluating the efficacy of combining thermal ablation and stereotactic 
spine radiosurgery (NCT02713269). 
Reimbursement 
At this point in time, the use of radiofrequency ablation for the treatment of 
spinal metastatic lesions is not reimbursed by the Austrian health care system. 
 
Discussion 
Overall, the strength of evidence on clinical effectiveness cannot be deter-
mined. For safety outcomes the strength of evidence is “very low”. 
Considering the findings of the included studies in this review, it seems that 
image-guided RFA with or without vertebroplasty might be a feasible and safe 
technique for patients with painful metastatic spinal lesions. In particular, 
since there were no serious complications reported. No therapy means intol-
erable pain for the patient. If other treatments are contraindicated, RFA (in 
combination with vertebroplasty) may be an effective treatment for pain re-
duction on the basis of the included studies. 
A major concern of most of the identified prospective studies is the low num-
ber of included patients. Especially, to identify rare complications, low pa-
tient numbers are insufficient. Another essential issue are the short follow-
up periods in the included studies. Yet, only one study had a follow-up of 60 
months. Therefore, reliable data of long-term safety and efficacy outcomes are 
missing. However, data collection is extremely difficult, because long-term 
follow-up is challenging in patients with metastatic spinal lesions due to high 
morbidity and mortality rates. 
Due to the palliative course of the disease and the limited life expectancy of 
patients with painful metastatic spinal lesions, an effective and safe therapy, 
such as RFA, to improve pain relief and HRQoL that can also be performed 
on an outpatient setting might be beneficial. 
 
Conclusion 
The natural course of metastatic spinal lesions is fatal with intolerable pain. 
Thus, on ethical grounds, every therapy providing pain relief and causes no 
major complications may be justified. The current evidence indicates that the 
assessed technology RFA is, under certain conditions, effective and safe for 
the treatment of painful metastatic spinal lesions. The intervention should 
only be performed in specialized centres and, if possible, with registry acqui-
sition for potential and rare adverse events. 
Due to the low quality of evidence of the included studies, we recommend 
radiofrequency ablation for metastatic spinal lesions with restrictions. The 
technology might be used for patients with metastatic spinal lesions as palli-
ative pain treatment in whom alternative treatments do not achieve sufficient 
effect or are contraindicated. 
A re-evaluation is recommended after 2021 because of relevant ongoing stud-
ies, including a registry study that may provide new evidence of the technology. 
3 ongoing studies 
no reimbursement  
of the intervention  
in Austria 
strength of evidence  
for clinical effectiveness 
not estimable; 
“very low” strength of 
evidence for safety 
outcomes 
 
RFA (in combination 
with vertebroplasty) 
might be a feasible, safe 
and effective technique 
for patients with painful 
metastatic spinal lesions 
 
small numbers of 
patients in prospective 
studies 
short follow-up periods 
(palliative) 
RFA is recommended 
with restrictions  
 palliative pain 
treatment in specialized 
centres and, if possible, 
with registry acquisition 
for potential and rare 
adverse events 
re-evaluation after 2021 
recommended 
Radiofrequency ablation for metastatic spinal lesions 
8 LBI-HTA | 2017 
Zusammenfassung 
Einleitung 
Indikation und therapeutisches Ziel 
Der Fokus dieser systematischen Übersichtsarbeit liegt auf Wirbelsäulenme-
tastasen. 
Viele TumorpatientInnen entwickeln im Laufe ihrer Erkrankung schmerzhaf-
te Metastasen in der Wirbelsäule, die die Wirbel zerstören. Diese Metastasen 
stellen die häufigste Ursache für chronische Schmerzen, Frakturen, vermin-
derte Beweglichkeit und Rückenmarkskompressionen bei TumorpatientIn-
nen dar [1, 2]. Daher leiden PatientInnen mit unbehandelten schmerzhaften 
Wirbelsäulenmetastasen häufig an Frakturen, verminderter Lebensqualität 
und eingeschränkter Mobilität. Dies kann wiederum negative Auswirkungen 
auf die Funktionsfähigkeit haben und zu Depressionen und Angstzuständen 
führen [2-4]. Die Behandlung von Wirbelsäulenmetastasen ist meist palliativ, 
da der Tumor im Stadium der Metastasenbildung schon weit fortgeschritten 
ist und PatientInnen ein mittleres Überleben von lediglich 3-6 Monate haben 
[5]. 
Beschreibung der Technologie 
Radiofrequenzablation (RFA) ist ein minimal invasives thermisches Ablati-
onsverfahren für solide Tumore [6, 7]. RFA wird bei Wirbelsäulenmetasta-
sen mit einem transpedikulären oder parapedikulären Ansatz durchgeführt. 
Der Eingriff erfolgt in Bauchlage unter Allgemein- oder Lokalanästhesie [1, 8]. 
RFA verwendet bildgebende Verfahren, um eine Nadelelektrode manuell in 
das Tumorgewebe einzuführen. Eine Kanüle und eine navigierbare Sonde 
werden verwendet, um die Metastase im Wirbelkörper zu erreichen. Über 
einen Radiofrequenzgenerator werden hochfrequente Wechselstromimpulse 
in das Tumorgewebe abgegeben [1, 9, 10]. Das durch Radiofrequenzenergie 
(50-90°C) erzeugte Wärmefeld bewirkt die Zerstörung des malignen Gewebes 
und schafft einen Hohlraum im Wirbelkörper [3]. Dadurch wird die sichere 
Eliminierung von vertebralen Metastasen nahe wärmeempfindlicher Struk-
turen wie dem Rückenmark ermöglicht [1, 11]. 
Zur Stabilisierung frakturgefährdeter Wirbelkörper kann als zusätzliche prä-
ventive Therapie im Anschluss an die RFA eine Vertebroplastie (Zementie-
rung des Wirbelkörpers) durchgeführt werden [12]. 
Wissenschaftliche Fragestellung 
Ist die RFA in Kombination mit oder ohne Vertebroplastie (oder anderen Zu-
satztherapien) im Vergleich zur Standardtherapie oder keiner Behandlung 
bei PatientInnen mit Wirbelsäulenmetastasen im Hinblick auf Schmerzen, 
Funktionsstatus, gesundheitsbezogener Lebensqualität und Komplikationen 
wirksamer und sicherer? 
 
  
Fokus: Metastasen in 
der Wirbelsäule (WS) 
viele Tumor-
patientInnen entwickeln 
WS-Metastasen, die die 
häufigste Ursache für 
chronische Schmerzen, 
Frakturen und Rücken-
markskompressionen 
darstellen 
RFA ist eine minimal-
invasive Intervention, 
die unter Allgemein- 
oder Lokalanästhesie 
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eine navigierbare 
Nadelelektrode wird 
unter Bildüberwachung 
in das Tumorgewebe 
eingebracht 
 
durch Wechselstrom 
wird malignes Gewebe 
zerstört 
 
Vertebroplastie zur 
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Forschungsfrage 
Zusammenfassung 
LBI-HTA | 2017 9 
Methoden 
Die Beantwortung der Forschungsfrage bezüglich Wirksamkeit und Sicher-
heit erfolgte anhand einer systematischen Literatursuche in folgenden Daten-
banken: 
 Medline via Ovid 
 Embase 
 The Cochrane Library 
 CRD (DARE, NHS-EED, HTA) 
 PubMed. 
Zusätzlich wurde eine Handsuche durchgeführt und es erfolgte eine ergän-
zende Studienanfrage bei einzelnen Herstellern. Die Studienauswahl, Daten-
extraktion sowie die Bewertung der methodischen Qualität der Studien erfolg-
te unabhängig durch zwei Autorinnen. Insgesamt wurden neun Publikationen 
für eine Datensynthese eingeschlossen. 
Die Daten, der für die Entscheidung herangezogenen Endpunkte, wurden 
aus den einzelnen Studien zusammengefasst und nach GRADE (Grading of 
Recommendations Assessment, Development and Evaluation) bewertet. 
Klinische Wirksamkeit 
Zur Bewertung der Wirksamkeit wurden die folgenden entscheidenden 
Endpunkte für eine Empfehlung herangezogen: 
 Schmerzreduktion 
 funktioneller Status und  
 gesundheitsbezogene Lebensqualität (HRQoL). 
Sicherheit 
Zur Bewertung der Sicherheit wurden die folgenden entscheidenden  
Endpunkte für eine Empfehlung herangezogen: 
 schwerwiegende Komplikationen 
 unerwünschte Ereignisse (verfahrensbezogen) 
 unerwünschte Ereignisse (nicht-verfahrensbezogen). 
 
Ergebnisse 
Verfügbare Evidenz 
Insgesamt konnten vier prospektive und fünf retrospektive einarmige Studien 
identifiziert werden, die den Einschlusskriterien entsprachen. Für retrospek-
tive Studien wurde ein Cut-Off von mehr als 30 PatientInnen als Einschluss-
kriterium festgelegt. 
Klinische Wirksamkeit 
Zur Beurteilung der Wirksamkeit der RFA für die Behandlung von Metasta-
sen in der Wirbelsäule konnten keine Vergleichsstudien identifiziert werden. 
Die einzigen Studien, die die Einschlusskriterien erfüllten, waren vier pros-
pektive einarmige, teilweise multizentrische Studien mit insgesamt 112 Pa-
tientInnen, die die Wirksamkeit der RFA in Kombination mit Vertebroplas-
tie beurteilten. 
systematische 
Literatursuche 
Handsuche,  
Anfrage bei Herstellern 
Studienbewertung  
nach GRADE 
entscheidende 
Endpunkte für 
Wirksamkeit … 
… und Sicherheit 
4 prospektive und  
5 retrospektive 
Einzelarm-Studien 
4 prospektive 
Einzelarm-Studien mit 
112 PatientInnen 
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Drei der eingeschlossenen prospektiven Studien berichteten von signifikanten 
Ergebnissen bei der Schmerzreduktion nach der Behandlung mit RFA und 
Vertebroplastie. Zwei der Studien bewerteten die gesundheitsbezogene Le-
bensqualität. Diese zeigte eine erhebliche Verbesserung im Verlauf der Fol-
low-up Zeiträume. Eine Studie verzeichnete kein Wiederauftreten von ver-
tebralen Metastasen, während die anderen eingeschlossenen Studien diesen 
Endpunkt nicht berichteten. 
Sicherheit 
In Abwesenheit von Daten aus kontrollierten Studien konnten auch für die 
Bewertung der Sicherheitsendpunkte keine Vergleiche von RFA mit ande-
ren Therapieoptionen durchgeführt werden. Insgesamt wurden Ergebnisse zu 
den Sicherheitsendpunkten in vier prospektiven Studien (112 PatientInnen) 
und in fünf retrospektiven Studien (471 PatientInnen) berichtet. 
Keine der eingeschlossenen Studien berichtete von schwerwiegenden Kompli-
kationen bei einer Behandlung von Wirbelsäulenmetastasen mit RFA. Über 
die einzelnen Studien hinweg traten unerwünschte Ereignisse (verfahrens-
bezogene oder nicht-verfahrensbezogene) bei 105 von insgesamt 583 einge-
schlossenen PatientInnen (18 %), die das jeweilige Follow-up durchlaufen 
sind, auf. 
Die am häufigsten berichteten verfahrensbezogenen unerwünschten Ereig-
nisse waren vermehrte Schmerzen und Taubheitsgefühle (7,8 %, 6/77 Pati-
entInnen). Die meisten unerwünschten Ereignisse, die nicht RFA-bezogen, 
aber durch die Vertebroplastie hervorgerufen wurden, waren Zementextrava-
sationen. Dieses unerwünschte Ereignis wurde von 67 PatientInnen berich-
tet (18,7 %, 67/358 PatientInnen). 
Laufende Studien 
Aktuell sind drei laufende Studien registriert. Ein Studienregister des STAR® 
Tumor-Ablationssystems (NCT02419703), eine laufende Studie über die Kom-
bination von RFA und Vertebroplastie (ChiCTR-INR-16010135) und eine 
Phase II Studie zur Bewertung der Wirksamkeit von thermischer Ablation 
in Kombination mit stereotaktischer Wirbelsäulen-Strahlenchirurgie   
(NCT02713269). 
Kostenerstattung 
In Österreich werden die Kosten der RFA zur Behandlung von  
Wirbelsäulenmetastasen derzeit nicht erstattet. 
 
Diskussion 
Das Ziel des vorliegenden Berichts war es, die klinische Wirksamkeit und 
Sicherheit der RFA (in Kombination mit Vertebroplastie) zu bewerten. Ins-
gesamt kann die Stärke der Evidenz für die klinische Wirksamkeit nicht be-
stimmt werden, da keine kontrollierten Studien zur Beurteilung der Wirk-
samkeit identifiziert werden konnten. Für die Sicherheitsendpunkte wurde 
die Evidenzstärke als „sehr gering“ eingestuft. 
In Anbetracht der Ergebnisse der eingeschlossenen Studien scheint die bild-
geführte RFA mit oder ohne anschließende Vertebroplastie eine durchführ-
bare und sichere Technik für PatientInnen mit schmerzhaften Metastasen in 
der Wirbelsäule zu sein. Vor allem da keine schwerwiegenden Komplikatio-
nen in Verbindung mit RFA in den Studien aufgetreten sind. Sollten andere 
Schmerzreduktion in  
3 Studien; 
Verbesserung der 
Lebensqualität in  
2 Studien 
zusätzlich  
5 retrospektive Studien 
mit 471 PatientInnen 
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Schmerzen und 
Taubheit 
 aufgrund von  
Zusatz-Therapien 
häufig: Zementaustritt 
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Behandlungen kontraindiziert sein und da keine Therapie für die betroffe-
nen PatientInnen häufig zu unerträglichen Schmerzen führt, kann RFA (in 
Kombination mit Vertebroplastie), auf der Grundlage der eingeschlossenen 
Studien, eine wirksame Behandlung zur Schmerzreduktion sein. 
Wesentlicher Kritikpunkt an der vorliegenden Evidenz ist die geringe Anzahl 
der PatientInnen in der Mehrzahl der eingeschlossenen prospektiven Studien. 
Zur Identifikation von seltenen unerwünschten Ereignissen könnte die kleine 
Fallzahl unzureichend sein. Ein weiterer essentieller Kritikpunkt sind die re-
lativ kurzen Nachbeobachtungszeiträume in den einzelnen Studien. Lediglich 
eine Studie hatte einen Nachbeobachtungszeitraum von 60 Monaten. Daher 
fehlen zuverlässige Daten über die längerfristigen Sicherheits- und Wirksam-
keitsergebnisse. Allerdings ist die Datenerhebung äußerst schwierig, da die 
Nachbeobachtung von PatientInnen mit Wirbelsäulenmetastasen aufgrund 
der hohen Morbidität und Mortalität eine große Herausforderung darstellt. 
Aufgrund des palliativen Verlaufs der Erkrankung und der begrenzten Le-
benserwartung von PatientInnen mit schmerzhaften Metastasen in der Wir-
belsäule, könnte eine wirksame und sichere Therapie, wie RFA, zur Schmerz-
linderung und Verbesserung der Lebensqualität, die auch auf ambulanter Ba-
sis durchgeführt werden kann, von Vorteil sein. 
Entscheidende Limitationen des vorliegenden Berichts sind: Es konnten keine 
randomisierten kontrollierten Studien identifiziert werden und retrospektive 
Studien mit weniger als 30 PatientInnen wurden ausgeschlossen. Deshalb ist 
davon auszugehen, dass die Fehlerquellen aufgrund von Bias und Störfakto-
ren hoch sind. Zusätzlich basieren die Ergebnisse der Studien auf subjektiven 
Angaben (z. B. Schmerz), was ebenfalls zu einer möglichen Verzerrung der 
Ergebnisse führen kann. 
 
Empfehlung 
Die Prognose von Wirbelsäulenmetastasen ist äußerst schlecht. Sie sind mit 
unerträglichen Schmerzen verbunden und die betroffenen PatientInnen ha-
ben eine maximale Überlebensdauer von 6 Monaten. Aus ethischen Aspekten 
kann demnach jede Therapie ohne schwerwiegende Komplikationen, die eine 
Schmerzlinderung erreicht, gerechtfertigt sein. Die gegenwärtige Evidenz deu-
tet darauf hin, dass RFA unter bestimmten Bedingungen wirksam und sicher 
für die Behandlung von schmerzhaften Wirbelsäulenmetastasen ist. Die In-
tervention sollte nur in spezialisierten Zentren erbracht und es sollte, soweit 
möglich, eine Registererhebung für potenzielle und seltene unerwünschte Er-
eignisse durchgeführt werden. 
Aufgrund der geringen Qualität der Evidenz, wird RFA für Wirbelsäulen-
metastasen nur mit Einschränkungen empfohlen. Die Technologie kann für 
PatientInnen mit metastasierten Wirbelsäulenläsionen, bei denen alternati-
ve Behandlungen nicht ausreichend oder kontraindiziert sind, als palliative 
Schmerzbehandlung durchgeführt werden. 
Eine Re-Evaluierung wird ab 2021 empfohlen, da es derzeit laufende Studien 
und ein Studienregister gibt, die möglicherweise einen wichtigen Einfluss auf 
die Einschätzung des Effekts haben können. 
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1 Scope 
1.1 PICO question 
Is radiofrequency ablation with/without vertebroplasty (or other add-on ther-
apies) in comparison to the standard of care (SoC) or no treatment in pa-
tients with metastatic spinal lesions more effective and safe concerning pain, 
functional status, health-related quality of life (HRQoL) and complications? 
 
 
1.2 Inclusion criteria 
Inclusion criteria for relevant studies are summarized in Table 1-1. 
Table 1-1: Inclusion criteria 
Population Patients with solitary fracture-related metastases of all entities in whom a curative 
tumor treatment (vertebral body extension and stabilization) is not indicated; 
patients in a palliative setting after maximal radiation dose or radiation-resistant 
lesions. 
ICD-10 code: C79.5 secondary malignant neoplasm of the bone and the bone marrow 
MeSH-terms: spinal neoplasms, catheter ablation 
Intervention Radiofrequency ablation (RFA) with/without vertebroplasty/other add-on therapies 
(e.g., radiation) 
All add-on therapies were included. 
MeSH term: Radiofrequency Catheter Ablation 
Control No treatment with RFA. 
Outcomes  
Efficacy  pain (pain relief) 
 functional status 
 health-related quality of life (HRQoL) 
 satisfaction with treatment 
 recurrence of vertebral metastases (local relapse) 
 mortality, improved survival 
Safety  complications 
 adverse events 
Study design  
Efficacy Randomised controlled trials 
Prospective non-randomised controlled trials 
Prospective case-series 
Safety Randomised controlled trials 
Prospective non-randomised controlled trials 
Prospective case-series 
Retrospective case-series (n>30 patients) 
 
PIKO-Frage 
Einschlusskriterien  
für relevante Studien 
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2 Methods 
2.1 Research questions 
Description of the technology 
Element ID Research question 
B0001 What is radiofrequency ablation? 
B0002 What is the claimed benefit of radiofrequency ablation? 
B0003 What is the phase of development and implementation of radiofrequency ablation? 
B0004 Who administers radiofrequency ablation and in what context and level of care is it provided? 
B0008 What kind of special premises are needed to use radiofrequency ablation? 
B0009 What supplies are needed to use radiofrequency ablation? 
A0020 For which indications has radiofrequency ablation received marketing authorisation  
or CE marking? 
A0021 What is the reimbursement status of radiofrequency ablation? 
 
Health problem and Current Use 
Element ID Research question 
A0001 For which health conditions and for what purposes is radiofrequency ablation used? 
A0002 What is the disease or health condition in the scope of this assessment? 
A0003 What are the known risk factors for vertebral metastases? 
A0004 What is the natural course of vertebral metastases? 
A0005 What are the symptoms and the burden of disease of vertebral metastases for the patient? 
A0006 What are the consequences of vertebral metastases for the society? 
A0024 How are vertebral metastases currently diagnosed according to published guidelines and  
in practice? 
A0025 How are vertebral metastases currently managed according to published guidelines and  
in practice? 
A0007 What is the target population in this assessment?  
A0023 How many people belong to the target population? 
A0011 How much is radiofrequency ablation of vertebral metastases utilised? 
 
Clinical Effectiveness 
Element ID Research question 
D0005 How does radiofrequency ablation affect symptoms and findings (severity, frequency)  
of painful vertebral metastases? 
D0006 How does radiofrequency ablation affect progression (or recurrence) of vertebral metastases? 
D0012 What is the effect of radiofrequency ablation on generic health-related quality of life? 
D0013 What is the effect of radiofrequency ablation on disease-specific quality of life? 
D0011 What is the effect of radiofrequency ablation on patients’ body functions? 
D0016 How does the use of radiofrequency ablation affect activities of daily living? 
D0017 Were patients satisfied with radiofrequency ablation? 
D0001 What is the expected beneficial effect of radiofrequency ablation on mortality? 
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Safety 
Element ID Research question 
C0008 How safe is radiofrequency ablation in comparison to the comparator(s)? 
C0002 Are the harms related to dosage or frequency of applying radiofrequency ablation? 
C0004 How does the frequency or severity of harms change over time or in different settings? 
C0005 What are the susceptible patient groups that are more likely to be harmed through the use  
of radiofrequency ablation? 
C0007 Is radiofrequency ablation associated with user-dependent harms? 
B0010 What kind of data/records and/or registry is needed to monitor the use of radiofrequency 
ablation? 
 
 
2.2 Sources 
Description of the technology 
 Handsearch in the POP and CRD databases for Health Technology 
Assessments, and in Google (for identifying manufacturers and  
product information) 
 Background publications identified in database search: see Section 2.3 
 Documentation provided by one manufacturer 
 Questionnaire completed by the submitting hospital 
 
Health problem and current use 
 Handsearch in the UpToDate database, the POP, and CRD databases 
for Health Technology Assessments and in Google 
 Background publications identified in database search: see Section 2.3 
 Documentation provided by one manufacturer 
 Questionnaire completed by the submitting hospital 
 Handsearch for management guidelines in the National  
Comprehensive Cancer Network and the Onkopedia Database 
 
  
Quellen:  
systematische Suche, 
Handsuche sowie 
Informationen eines 
Herstellers & des 
einreichenden 
Krankenhauses 
Methods 
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2.3 Systematic literature search 
The systematic literature search was conducted between 28th and  
29th of December 2016 in the following databases: 
 Medline via Ovid 
 Embase 
 The Cochrane Library 
 CRD (DARE, NHS-EED, HTA) 
 PubMed 
The systematic search was limited to articles published in English or German. 
After deduplication, overall 293 citations were included. The specific search 
strategy employed can be found in the Appendix (Chapter “Literature search 
strategies”). 
One manufacturer from the most common product (STARTM – radiofrequency 
ablation system for vertebral metastasis) submitted 6 publications of which 0 new 
citations were identified. 
The submitting hospital sent 12 publications of which 3 new citations were 
identified. 
By hand-search, additional 2 records were found, resulting in overall 299 hits. 
One Health Technology Assessment (HTA) from the Comite d´Evaluation et de 
Diffusion des Innovations Technologiques (CEDIT) that analysed a similar re-
search question was identified by the systematic search [11]. Because the HTA 
is written in French, only the reference list was screened for additional rele-
vant citations. In this reference list, we could identify another HTA, which 
provided background information on malignant spinal metastases and on 
technologies for identifying patients at high risk of vertebral fracture and 
spinal cord compression [7]. 
 
  
systematische 
Literatursuche in  
5 Datenbanken  
insgesamt 299 
Publikationen 
identifiziert 
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2.4 Flow chart of study selection 
Overall 299 hits were identified. The references were screened by two inde-
pendent researchers (KR, BP) and in case of disagreement a third researcher 
was involved to solve the differences. The selection process is displayed in 
Figure 2-1. 
 
* 5 publications presented sub-analytical results of 4 already included observational studies. 
Therefore, only the overall data of the primary studies are presented in the outcomes. 
Figure 2-1: Flow chart of study selection (PRISMA Flow Diagram) 
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2.5 Analysis 
The data retrieved from the selected studies (see Chapter 2.4) were systemat-
ically extracted into a data-extraction-table (see Appendix Table A-1, Table 
A-2, Table A-3). No further data processing (e.g., indirect comparison) was 
applied. The studies were systematically assessed for quality and risk of bias 
by two independent researchers (KR, BP) using the IHE Risk of Bias check-
list for case series [13] presented in the Appendix (see Table A-4). 
 
 
2.6 Synthesis 
Based on the data-extraction-table (see Appendix Table A-1, Table A-2, Table 
A-3), data on each selected outcome category were synthesised across studies 
according to GRADE (Grading of Recommendations Assessment, Develop-
ment and Evaluation) [14]. The research questions were answered in plain 
text format with reference to GRADE evidence tables that are included in 
Table 7-1. 
 
 
Datenextraktion  
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mittels GRADE 
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3 Description and technical 
characteristics of technology 
Features of the technology and comparators 
B0001 – What is radiofrequency ablation? 
The treatment of unresectable tumours and metastases in the area of the spine 
has made a substantial progress over the last decades. The treatment options 
mostly include cytoreductive therapies, i.e., radiation, hormonal ablation, and 
chemotherapy, but also of treatments that do not directly attack the tumour 
cells, but inhibit osteoclast activity. However, in some patients, all of these 
treatment options cannot provide sufficient symptom control [8, 15]. 
Radiofrequency ablation (RFA) is an image-guided minimally invasive ther-
mal ablation procedure for solid tumours [6, 7]. In the last years, RFA has 
emerged as a feasible option in the palliative treatment of vertebral metasta-
ses because of short procedure times, its minimally invasive, and its capacity 
to be performed on an ambulatory basis [1, 8]. 
RFA for metastatic spinal lesions is performed using a transpedicular or para-
pedicular approach. The approach is either percutaneous, endoscopic, or sur-
gical. During the procedure, the patient is positioned face down and sedated 
using conscious sedation or general anaesthesia [1, 8]. 
RFA uses imaging guidance to manually insert a needle electrode into the 
tumour tissue. The imaging guidance with ultrasound (US), fluoroscopy, com-
puted tomography (CT), or magnetic resonance imaging (MRI) helps pre-
venting injury to vascular structures. To access the metastasis in the vertebral 
body, a cannula and a navigable probe is used. Via a radiofrequency genera-
tor, high frequency alternating current pulses are emitted into the tumour 
tissue [1, 9, 10]. The heat field generated by radiofrequency energy (50-90°C) 
causes the destruction of the malignant tissue and creates a cavity in the ver-
tebral body [3]. These features allow for the safe destruction of vertebral me-
tastases near heat-sensitive structures such as the spinal cord [1, 11]. 
If the vertebral body implies a risk of fracture after RFA, an additional pre-
ventive treatment with vertebroplasty (cementation of the vertebral body) can 
be performed [12]. Vertebroplasty following RFA may be especially indicat-
ed in weight-bearing bones such as the vertebrae [16]. However, subsequent 
vertebroplasty carries a risk of spinal canal compromise and should only be 
performed with caution and by qualified physicians [15, 17]. 
RFA is not indicated if the metastasis is adjacent to neurological structures 
in order to avoid major complications such as neurological injury and to avoid 
fracture of large lesions in the vertebrae [18]. 
Several devices are in use for ablation of metastatic spinal lesions. The two 
most frequently used RFA-systems in the included studies are the STAR 
Tumor Ablation System and the CAVITY SpineWand: 
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STAR® Tumor Ablation System 
This ablation probe has a bipolar extensible radiofrequency electrode at the 
top of the articulated distal segment. The segment can be curved up to 90° 
and, therefore, is able to access multiple areas of the tumour. The system 
comprises also a combination of two thermocouples, which enable real-time 
monitoring of temperature. This bipolar design reduces the risk of skin burn 
and does not require a grounding pad [9, 19]. 
CAVITY-SpineWand® 
The CAVITY-SpineWand® probe creates a cave in the tumour tissue by plas-
ma generation (coblation-controlled ablation) at a low temperature (about 
42°C) on the basis of plasma-mediated high-frequency energy. Coblation (ra-
diofrequency-based plasma ablation) means a controlled ablation with a pre-
bent plasma probe. The probe can be rotated so the ablation can take place in 
several directions. Coblation can be combined with additional procedures, in 
particular with vertebroplasty [8, 20, 21]. 
B0002 – What is the claimed benefit of radiofrequency ablation? 
Several advantages are discussed for RFA in comparison to other treatments: 
cell death of the metastasis can be achieved immediately, accurate control of 
the lesion size, monitoring of the lesion temperature, electrode placement with 
a percutaneous image-guided procedure, and RFA can be performed under 
local anaesthesia and conscious sedation [6]. 
According to the information provided by the submitting hospital, RFA for 
metastatic spinal lesions may lead to immediate stabilization/prevention of 
fractures, immediate pain reduction, shortened length of hospital stay (1d), 
and shorter treatment duration. Therefore, an increased HRQoL and func-
tionality may be recorded. Another advantage of this method is the minimal-
ly invasive approach (low potential for injuries of sensitive adjacent neural 
structures) as well as that interrupting chemotherapy is not necessary. Fur-
thermore, the treatment represents an alternative to the therapy by radiation. 
B0003 – What is the phase of development  
and implementation of radiofrequency ablation? 
RFA was first described in 1992 as an auspicious technique for the treatment 
of osteoid osteomas [22, 23]. According to the information provided by the 
submitting hospital and the included studies, RFA is not a clinical standard 
for the treatment of metastatic spinal lesions. 
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Administration, Investments, personnel and  
tools required to use the technology and the comparator(s) 
B0004 – Who administers radiofrequency ablation and in what context 
and level of care is it provided? 
B0008 – What kind of special premises are needed to use  
radiofrequency ablation? 
B0009 – What supplies are needed for radiofrequency ablation? 
According to the information received by the submitting hospital, neurosur-
gery departments of university hospitals with interdisciplinary tumour boards 
perform the intervention. The intervention is performed in general anaesthe-
sia or conscious sedation and in prone position. RFA requires placing of the 
electrode under imaging guidance straight into the metastasis [4, 6]. 
A close interdisciplinary cooperation between the orthopaedic surgeons and 
spine surgeons with other specialists such as radiologists, radiotherapists, on-
cologists, histopathologists, pain therapists, physiotherapists etc. is of critical 
importance for the treatment of vertebral metastases [8, 20]. The appropriate 
therapy has to be carefully and individually planned on the basis of several 
criteria and parameters (clinical, radiological, histopathological, etc.) [9, 17, 
18]. 
Constant follow-up examinations should be performed, clinical and radiolog-
ical, in order to exclude local recurrence, relaxations, and fractures and to as-
sess the condition, satisfaction, HRQoL, and pain relief. Postoperative local 
radiotherapy and chemotherapy may be performed to cope with the primary 
tumour and possible other metastases [8]. 
RFA can also be performed in an outpatient setting under conscious sedation 
because it is associated with short recovery [4]. 
 
Regulatory & reimbursement status 
A0020 – For which indications has radiofrequency ablation  
received marketing authorisation or CE marking? 
RFA for metastatic spinal lesions is a procedure and is therefore not subject 
to regulation by the Food and Drug Administration (FDA). However, the 
FDA regulates RFA devices and hence, there are various devices listed in 
the FDA 510(k) Premarket Notification database. The following products are 
an excerpt of devices that received FDA clearance (generators and lesion 
probe devices): 
 OsteoCool® V-2 RF Ablation System for palliative treatment in spinal 
procedures by ablation of metastatic malignant lesions in a vertebral 
body (Baylis Medical Company Inc., approved 2015) 
 STAR® Tumor Ablation System for palliative treatment in spinal pro-
cedures by ablation of metastatic malignant lesions in a vertebral body 
(SpineSTAR® ablation instrument and the MetaSTAR® generator)   
(DFine Inc., approved 2010/Merit Medical Systems, Inc.) 
 ArthroCare® Cavity SpineWand® for resection, ablation, and coagula-
tion of soft tissue and haemostasis of blood vessels in percutaneous, 
intraoperative, or spinal procedures including the creation of a cavity 
in malignant lesions in a vertebral body (ArthroCare Corporation, ap-
proved 2007) 
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 Cool-tip RF System (generator and accessories) for the use in percuta-
neous, laparoscopic, intraoperative coagulation and ablation of tissue 
such as partial or complete ablation of non-resectable liver lesions and 
osteoid osteoma tumors within bone (Valleylab, approved 2006) 
 RITA® System (RF generator and electrosurgical devices) supplies en-
ergy for use in electrosurgery and is indicated for use in percutaneous, 
laparoscopic, or intraoperative coagulation and ablation of soft tissue, 
including the partial or complete ablation of non-resectable liver le-
sions and the palliation of pain associated with metastatic lesions in-
volving bone in patients who have failed or are not candidates for 
standard pain therapy (RITA Medical Systems Inc., approved 2004) 
 ArthroCare Orthopedic Electrosurgery System for resection, ablation, 
and coagulation of soft tissues and hemostasis of blood vessels in or-
thopaedic, arthroscopic, and spinal procedures (ArthroCare Corpora-
tion, approved 1999) 
The STAR® Tumor Ablation System has also received CE Marking according 
to the information received by the manufacturer. We were not able to identi-
fy a comprehensive list of other currently CE marked RFA systems and we 
refrained from a manual search for the CE marking of various RFA compo-
nents. 
A0021 – What is the reimbursement status of radiofrequency ablation? 
Currently, RFA for metastatic spinal lesions is not included in the Austri-
an DRG-system (Leistungsorientierte Krankenanstaltenfinanzierung/LKF). 
Therefore, the intervention itself is not reimbursed by the Austrian health 
care system. However, the intervention could be billed under another code, 
such as for erection and filling of the vertebral body by percutaneous punc-
ture (e.g., RFA in combination with vertebroplasty) (Code LH020 – Aufrich-
tung und Füllung des Wirbelkörpers durch perkutane Punktion) [24]. 
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4 Health Problem and Current Use 
Overview of the disease or health condition 
A0001 – For which health conditions and for what purposes  
is radiofrequency ablation used? 
RFA is used for patients with vertebral and bone metastases of all entities 
and with fracture endangering, in whom a curative tumour therapy (e.g., ra-
diation therapy) is not indicated or contraindications may occur [9]. The treat-
ment with RFA should only be performed in patients with localised moder-
ate pain (>4 VAS score) [2, 16]. 
Metastatic spinal lesions are often unstable and therefore, in most cases, can-
not be treated with a conservative therapy (e.g., radiation) in most cases [21]. 
Additionally, patients who do not respond to a conventional treatment often 
have a contraindication to radiation therapy and may benefit from RFA [7]. 
Furthermore, this intervention can be performed in patients who cannot or 
will not undergo surgery.[15]. The intervention is not curative, but palliative 
[25]. 
Vertebral metastases are adjacent to nerves and there is a risk of nerve injury 
in the spinal cord that can be accompanied with curative treatments [26]. 
RFA is contraindicated for patients with asymptomatic vertebral compression 
fracture, effective medical therapy (e.g. analgesics), infections, coagulopathy, 
and tumour causing spinal cord compression [27]. 
A0002 – What is the disease or health condition  
in the scope of this assessment?  
In the scope of this assessment, vertebral metastases are the condition of in-
terest. Overall, bone metastases are a common manifestation of various types 
of solid cancers, e.g. those arising in the breast, lung and prostate [2, 3]. 
A0003 – What are the known risk factors for vertebral metastases? 
The primary risk factor for vertebral metastases is the progress of the primary 
cancer. Risk factors for vertebral metastases depend on the primary cancer. 
Vertebral metastases are more often stemming from primary tumours in the 
lung, breast, and prostate than from other tumour types (e.g., melanoma). 
There are multiple additional risk factors: progression of the primary cancer, 
tumour spread, stage of disease etc. [7]. 
A0004 What is the natural course of vertebral metastases? 
Many tumour patients develop painful vertebral metastases in the course of 
their disease, which destroy the vertebrae. These metastases represent the 
most common cause of chronic pain, fractures, reduced mobility and spinal 
cord compression [1, 2]. Therefore, patients with untreated painful vertebral 
metastases may suffer from several complications, e.g., fractures, decreased 
HRQoL, decreased mobility, and reduced performance status. Consequent-
ly, it can have negative effects on the functional capacity and can lead to de-
pression and anxiety states [2-4]. The treatment of metastatic spinal lesions 
is usually palliative [5]. 
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Besides the lung and liver, the bone is one of the most commonly affected 
organs by metastases [28]. Vertebral metastases are the most common bone 
metastases because of the high hematopoietic activity and vascularization of 
the vertebrae [15]. 
Patients with osseous metastatic disease have a limited life expectancy with 
an average median survival time of 3-6 months [6]. 
 
Effects of the disease or health condition  
on the individual and society 
A0005 – What are the symptoms and the burden of disease  
of vertebral metastases for the patient? 
Patients in a progressed tumour stage can develop symptoms of paraplegia or 
massive pain because of a local spinal process. In many cases, those patients 
cannot be treated with surgery due to a reduced general condition and an 
adverse prognosis of the underlying disease [29]. Palliative care for patients 
with vertebral metastases can be challenging. Most patients have a very poor 
HRQoL because of intolerable pain. About 90% of the patients experience 
pain [9, 15, 30]. Another important factor is the risk of pathological fractures 
and spinal instability of the vertebral body, hypercalcemia, or spinal cord 
compression due to progression of metastatic spinal lesions [2, 28]. 
A palliative approach, such as minimally invasive procedures, can be a useful 
treatment option [29]. 
A0006 – What are the consequences  
of vertebral metastases for the society? 
Due to the aging population and the fact that higher age is the main risk fac-
tor for cancer, the incidence of cancer will increase over time [31]. In Aus-
tria, 38,908 newly diagnosed cancer patients were recorded in 2014. Of those, 
about 12% have already been diseased by remote metastases [32]. Bone me-
tastases are very common in patients with metastasised cancer whereby the 
vertebrae is most frequently affected (~40%) [9]. 
Data on the actual number of patients affected by vertebral metastases could 
not be identified. 
 
Current clinical management of the disease or health condition 
A0024 – How are vertebral metastases currently diagnosed according  
to published guidelines and in practice? 
No Austrian guidelines for the diagnosis (and treatment) of vertebral metas-
tases were identified. Depending on the primary tumour, several internation-
al guidelines can be found on the diagnosis and treatment of lung, prostate, 
or breast cancer. These guidelines mostly include a section for remote me-
tastases, e.g., the guideline of the Association of the Scientific Medical Socie-
ties in Germany (Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen 
Fachgesellschaften e.V., AWMF) for “Interdisciplinary S3 guideline for the 
diagnosis, therapy and aftercare of breast cancer” (Interdisziplinäre S3-Leit-
linie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms). An 
intensified instrumental and laboratory diagnosis with chest X-ray, bone scin-
tigraphy, CT, PET, or MRI as well as blood count determination, serum bio-
chemistry, or tumour marker determination belong to the diagnosis of metas-
tases and are only indicated in clinical abnormalities [33]. 
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The diagnosis of the tumour or the vertebral metastases has to be confirmed 
clinically, radiologically, and histologically in each patient [8]. The diversity 
of clinical and radiological presentations may elucidate why there is no op-
timal treatment for vertebral metastases [10]. 
A0025 – How are vertebral metastases currently managed  
according to published guidelines and in practice? 
Standard of care treatment options for vertebral metastases include localized 
therapies (radiation therapy and surgery), systemic therapies (chemotherapy, 
hormonal therapy, radiopharmaceuticals and bisphosphonates), and analge-
sics (opioids and nonsteroidal anti-inflammatory drugs). The mainstay of 
treatment is external beam radiotherapy, but 20-30% of patients do not ex-
perience accurate pain relief after radiotherapy [1, 3, 34]. A complete removal 
of vertebral metastases is not possible with these therapy approaches and fur-
thermore, there is a considerable risk of injury of the healthy tissue. In addi-
tion, for many patients with a reduced general condition, major surgical pro-
cedures are contraindicated in the vertebrae [8]. 
In either case, in the curative as well as the palliative therapy, objectives of 
the operative treatment are a least possible traumatization of the soft tissues 
and bones, in addition to the pain reduction and the improvement of HRQoL 
by: 
 using minimally invasive techniques, 
 the reduction of blood loss, 
 maintaining the stability of the vertebrae and spinal segments, 
 the correction of deformities or the reduction of compression  
fractures, 
 the decompression and dilatation of the spinal canal with as  
complete as possible removal of the tumour tissue, 
 the avoidance of fractures in case of massive osteolysis of the  
vertebral body [8]. 
For stabilisation and prevention of fracture in weight-bearing bones, a verte-
broplasty can be routinely performed into the ablated cavity [9]. 
 
Target population 
A0007 – What is the target population in this assessment? 
The target population in this assessment are, according to the information 
received by the submitting hospital, patients with solitary fracture-related me-
tastases of all entities in whom a curative tumour treatment (vertebral body 
extension and stabilization) is not indicated in a palliative setting after max-
imal radiation dose or with radiation-resistant lesions. 
It can be assumed that the target population for the intervention is small [11]. 
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A0023 – How many people belong to the target population?  
Overall, the spine is most frequently affected by bone metastases accounting 
for 40% of all bone metastases. Patients with breast or prostate cancer devel-
op metastases in the spine in about 70-90% of the cases, and patients with 
lung, kidney, or thyroid cancer about 30-40% [9]. Due to the high vasculari-
zation of adults’ vertebrae, various patients develop metastases in the spine 
[1, 34]. At the time of death, about 80% of cancer patients are affected by bone 
metastases and of those, about 50% by vertebral metastases [3, 15]. 
A0011 – How much is radiofrequency ablation  
of vertebral metastases utilised? 
According to the information provided by one Austrian hospital, the annual 
frequency in this hospital is estimated to be 12 RFA procedures of vertebral 
metastases. No total estimations were provided regarding the annual frequen-
cy in Austria. 
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5 Clinical effectiveness 
5.1 Outcomes 
Radiofrequency ablation for metastatic spinal lesions is primarily used to re-
duce the pain in the vertebrae of palliative patients to improve their HRQoL. 
Radiofrequency ablation devices are not used for a curative treatment of os-
seous cancers and metastases of the spine. Hence, the intervention does not 
influence patients’ survival. Therefore, this outcome was not listed as crucial 
for the recommendation. 
The following outcomes were defined as crucial to derive a recommendation: 
 Pain relief 
 Health-related quality of life (HRQoL) 
 Functional status 
Further outcomes were defined as important, but not crucial to derive  
a recommendation: 
 Satisfaction with treatment 
 Recurrence of vertebral metastases 
 Mortality, improved survival 
Changes in pain intensity and pain relief were measured in all but one of the 
included studies with the Visual Analogue Scale (VAS), the Numeric Rating 
Scale (NRS), or the Numerical Pain Rating Scale (NPRS). One study did not 
report any pain assessment tool [29]. 
The HRQoL was assessed by various tools: the included studies used the 
FACT-G7, FACT-BP [1], and the QoL Oswestry Index [22]. 
The functional status was measured in 2 studies using the Modified 
Oswestry Disability Index (MODI) [1]. 
The individual scores for pain, functional status, and HRQoL measurements 
will be further explained in the evidence tables (see Appendix Table A-1) where 
applicable. 
 
 
5.2 Included studies 
To assess the effectiveness of radiofrequency ablation for metastatic spinal 
lesions, we could not identify any comparative studies. The only studies that 
met our inclusion criteria were four prospective single arm, partly multicen-
tric, studies [1, 22, 26, 29] with a total of 112 patients, which assessed the ef-
fectiveness of radiofrequency ablation combined with vertebroplasty. 
The mean age of patients ranged from 61 to 67.8 years across trials. The fe-
male study participants were underrepresented in all but one study (100%; 
range 33.3-100%) [22]. The mean follow-up of the studies was 3, 4.5, and 20.4 
months [1, 22, 26]. One study reported the outcomes only 24-48 hours post-
treatment [29]. 
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Inclusion criteria differed slightly between studies. Across studies, patients 
were eligible for inclusion if they had painful vertebral metastases and were 
unresponsive to previous treatments (e.g. analgesics, radiation, or chemo-
therapy). Other inclusion criteria were: absence of neurological deficits, pain 
increase during movement, intervertebral tumour spread, and risk of para-
plegia and fracture. For detailed information see Appendix (Table A-1). 
Patients with heart pacemakers or other electronic device implants, risk of 
bleeding, acute infections, or allergies to anaesthesia etc. were contraindicat-
ed for RFA treatment and hence usually excluded. 
Four different RFA systems were used in the studies: the STAR Tumour Ab-
lations System (DFine Inc., USA) in [1], the CelonLab Power & Celon Aqua-
flow III (Celon AG Medical Instruments, Germany) in [29], the Celon Pro 
Surge & CelonPower Systen (Celon AG Medical Instruments, Germany) in 
[22], and the Cool-tip RF Ablation System (Valleylab, USA) in [26]. 
Loss to follow-up ranged from 0 [26] to 32% in [1], 2 studies did not report 
on loss to follow-up [22, 29]. 
Study characteristics and results of included studies are displayed in Table 
A-1 and in the evidence profile in Table 7-1. 
 
 
5.3 Results 
Morbidity (Pain) 
D0005 – How does radiofrequency ablation affect symptoms  
and findings (severity, frequency) of painful vertebral metastases? 
All four prospective studies reported outcomes on pain: two prospective stud-
ies reported pain reduction outcomes as changes in VAS scores [22, 26] and 
in one study as changes in NPRS scores [1]. Both scales range from 0 (no pain) 
to 10 (worst possible pain). The last prospective study only reports the per-
centage of patients with pain reduction without specification of the tool [29]. 
Three of those studies reported significant pain relief after the treatment with 
RFA, and in most cases with an additional treatment of vertebroplasty. The 
differences in pain relief can be explained by several factors including differ-
ences in tumour types or the number of painful sites previously radiated. 
One study reported a statistically significant decrease in pain (decrease by 2.2, 
p<0.0001) at one month (decrease by 3.3, p<0.0001) as well as three months 
(decrease by 3.8, p<0.0001) post treatment in comparison to baseline pain 
scores [1]. 
In the second study, pain was significantly decreased in all patients by 4.8 
points (p<0.00005) compared to baseline at one week post-intervention. 6 out 
of 10 patients received vertebroplasty after RFA, but no difference in pain 
was reported. In addition, in 90% of the included patients (9/10), pain relief 
sustained until the moment of death [26]. 
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The third study performed RFA in the first group (n=8) and RFA in com-
bination with vertebroplasty in the second group (n=8) of patients. No signif-
icant differences in pain relief were reported between the groups. This study 
reported a significant decrease in pain post-intervention in both groups (2.4 
in group 1 (p<0.018) and 2.6 in group 2 (p<0.005)). After a follow-up of 15-
36 months, the study stated an ongoing statistically significant decrease in 
pain in both groups compared to baseline (3.9 in group 1 (p<0.008) and 4.1 
in group 2 (p<0.005)) [22]. 
The last prospective study only stated that a proportion of patients (19 cases; 
52.8%) reported post-interventional pain reduction [29]. 
D0006 – How does radiofrequency ablation affect progression  
(or recurrence) of vertebral metastases? 
To answer this research question, the outcome “recurrence of vertebral me-
tastases (local relapse)” was used. 
This outcome was reported in one prospective study with 16 patients and a 
mean follow-up of 20.4 months. In none of the patients who underwent RFA 
or RFA in combination with vertebroplasty a local relapse of the vertebral 
metastases was reported [22]. 
 
Health-related quality of life 
D0012 – What is the effect of radiofrequency ablation  
on generic health-related quality of life? 
D0013 – What is the effect of radiofrequency ablation  
on disease-specific quality of life? 
HRQoL has been assessed in 2 prospective studies with different instruments. 
One prospective study used cancer-specific health-related quality-of-life in-
struments, the Functional Assessment of Cancer Therapy-General 7 (FACT-
G7) and Functional Assessment of Cancer Therapy Quality-of-Life Measure-
ment in Patients with Bone Pain (FACT-BP)1 to assess the HRQoL. This 
study observed statistically significant improvement in both scores compared 
to baseline throughout the follow-up of 1 month (improvement of 4.8 in FACT-
G7 and 14.7 in FACT-BP) and 3 months (improvement of 5.2 in FACT-G7 
and 16.3 in FACT-BP) [1]. 
Another prospective study used the Oswestry Disability Questionnaire2 for 
assessing HRQoL. This study performed RFA in the first group (n=8) and 
RFA in combination with vertebroplasty in the second group (n=8). No sig-
nificant differences in HRQoL were reported between groups. After 3-6 months  
                                                             
1 The FACT-G7 is abbreviated to seven evaluable questions and it is considered a rapid 
version of the FACT-G that has 27 questions. FACT-BP is specifically designed for 
use in cancer patients with bone pain and it contains 15 evaluable questions. Each 
questionnaire provides a calculation to generate a composite score. Higher scores 
are interpreted as greater patient quality of life and lower scores are interpreted as 
lower patient quality of life. FACT-G7 has a scale 0-28 and FACT-BP 0-60. 
2 The Oswestry Disability Index (ODI) is a validated scale comprised of ten questions 
designed to assess pain intensity and activities of daily living. The ODI ratings and 
corresponding categories are 0–20 (minimal disability), 20–40 (moderate disability), 
40–60 (severe disability), 60–80 (crippled) and 80–100% (bed bound). 
keine signifikanten 
Unterschiede zwischen 
RFA und RFA in 
Kombination mit 
Vertebroplastie; 
1 weitere Studie 
berichtet lediglich von 
einer Schmerzreduktion 
in 19 Fällen  
post-interventionell; 
Endpunkt Lokalrezidive: 
 
in einer prospektiven 
Studie (~20,4 Monate 
Nachbeobachtung)  
sind keine Lokalrezidive 
aufgetreten 
Endpunkt 
Lebensqualität 
 
Signifikante 
Verbesserung der 
Lebensqualität nach  
1 und 3 Monaten  
(1 Studie) 
1 weitere Studie: 
signifikante 
Verbesserung mit RFA 
(3-6 Monate)  
Radiofrequency ablation for metastatic spinal lesions 
32 LBI-HTA | 2017 
in the first group and after 15-36 months in the second group, the score signif-
icantly improved by 31% compared to baseline. The improvement in HRQoL 
right after the treatment was reported the same for both groups (significant 
improvement of 30% compared to baseline). Thus, it is a categorical improve-
ment in HRQoL from “crippled” to moderate disability, but no further im-
provement occurred during follow-up [22]. 
The remaining 2 studies did not report this outcome. 
 
Functional status 
D0011 – What is the effect of radiofrequency ablation  
on patients’ body functions? 
None of the studies reported results on patients’ body functions. 
D0016 – How does the use of radiofrequency ablation affect activities  
of daily living? 
One of the included prospective studies provided Modified Oswestry Disa-
bility Index (MODI)3 data on back-related disability with statistical signifi-
cant improvement in short term (1 month: 40%) and midterm (3 months: 
37%) post-treatment compared to baseline (52.9%). That represents an im-
provement in functional status from severe to moderate disability [1]. The 
remaining 3 studies did not report on this outcome [22, 26, 29]. 
Because functionality and HRQoL are both related with pain, there are un-
clear interfaces between the MODI and ODI scores. 
 
Patient satisfaction 
D0017 – Were patients satisfied with radiofrequency ablation? 
None of the included studies reported results on patient satisfaction. 
 
Mortality 
D0001 – What is the expected beneficial effect  
of radiofrequency ablation on mortality? 
Mortality (improved survival) is an important outcome that is, however, not 
crucial for assessing the clinical effectiveness of RFA because it is a palliative 
treatment that does not aim for life-prolonging effects. 
Only two studies reported outcomes on mortality: one study reported 5 de-
ceased patients (10%) during the follow-up period of 3 months [1]. Another 
study followed the total of 10 patients until their death, median of 4.5 months 
(100%) [26]. Since none of the studies included a control group, they could 
not provide any serious information on a possible survival prolongation. 
 
                                                             
3 The Modified Oswestry Disability Index (MODI) is a validated scale comprised of 
ten questions designed to assess pain intensity and activities of daily living. The 
MODI ratings and corresponding categories are 0–20 (minimal disability), 21–40 
(moderate disability), 41–60 (severe disability), 61–80 (crippled) and 81–100% (bed 
bound). 
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6 Safety 
6.1 Outcomes 
The following outcomes were defined as crucial to derive a recommendation: 
 Complications: 
 Major complications 
 Adverse events (procedure-related) 
 Adverse events (not procedure-related) 
According to the Society of Interventional Radiology classifications C-E, a ma-
jor complication is an event that resulted in substantial morbidity or disabil-
ity, an increase in the level of care, admission to the hospital, or substantial 
prolongation of the hospital stay [26]. 
Procedure-related Adverse Events are complications that are associated with 
the intervention. Possible procedure-related complications are events associ-
ated with anaesthesia, infections, damages to nerves or blood vessels, bleed-
ing, or the occurrence of blood clots (e.g. thrombosis). 
An Adverse Event is any untoward medical occurrence, unintended disease or 
injury or any untoward clinical signs (including an abnormal laboratory find-
ing) in subjects, users, or other persons whether or not related to the investi-
gational medical device. This includes events related to the investigational 
device or related to the procedures involved (any procedure in the clinical in-
vestigation plan).4 
 
 
6.2 Included Studies 
There are no comparative studies to assess the safety of radiofrequency abla-
tion. In order to assess safety-related outcomes, we accepted all published evi-
dence, except for retrospective studies. We only included studies with more 
than 30 patients. 
We identified four prospective single arm studies that assessed the safety of 
RFA in a total of 112 patients besides the clinical effectiveness [1, 22, 26, 29]. 
Patient and study characteristics are displayed in Chapter 5.2. 
In addition, we identified five retrospective single arm studies that assessed 
the safety of radiofrequency ablation in a total of 471 patients [4, 8, 12, 15, 
25]. 
 
                                                             
4 http://ec.europa.eu/consumers/sectors/medical-devices/files/meddev/2_7_3_en.pdf 
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The mean age of patients ranged from 62.7-69.6 years across these studies. The 
percentage of female participants was more than 57% in all but one study 
(39%) [25] with a maximum of up to 62.4% [8]. One study did not report the 
baseline characteristics for age and gender [15]. All studies included patients 
with painful vertebral metastases, intravertebral tumour spread, disease pro-
gression and fractures with instability. 
The follow-up of the studies was 2-4 weeks [12], 1 month [4], ≥6 months [15, 
25], and up to 60 months [8]. Loss to follow-up ranged from 3.1 [8] to 61% 
[25]. The high loss to follow-up rate in [25] is probably attributable to the fol-
low-up of 278-617 days and a more severe progression of the primary cancer 
at study entry (see Appendix Table A-1, Table A-2, Table A-3). 
For two of the included retrospective studies, it can be assumed, but it is not 
clearly stated, that observed patient populations overlap (some of the 72 pa-
tients included in [4] are assumed to be summarized in the 92 patients of 
[15]). We decided to report outcomes of these studies separately, but conse-
quently, data may be imprecise. 
Study characteristics and results of included studies are displayed in Table 
A-1, Table A-2 and Table A-3 and in the evidence profile in Table 7-1. 
 
 
6.3 Results 
Patient safety 
C0008 – How safe is radiofrequency ablation in comparison  
to the comparator(s)? 
There is no direct comparator to RFA therapy. 
None of the included studies reported major complications with the use of 
RFA. 
Overall, adverse events (procedure-related or not procedure-related) occurred 
in 105 patients who completed the follow-up, out of 583 included patients 
across the studies (18%). 
Adverse events (procedure-related) 
The most frequent adverse events reported were increased pain and numb-
ness (7.8%, 6/77 patients) [25, 29], and post-procedure radicular symptoms 
and pain (4.6%, 5/109 patients) [4, 12]. Other occurred procedure-related ad-
verse events were epidural extravasation (5.4%, 2/37 patients) [12], transient 
nerve injury (10%, 1/10) [26], unilateral monoradiculopathy (2.4%, 1/41), and 
“heavy legs” with paraesthesia (2.4%, 1/41) [25]. 
Four of the included studies did not report any procedure-related adverse 
events [1, 8, 15, 22]. 
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Adverse events (not procedure-related) 
The most frequent adverse event reported, which is not RFA-related, but ver-
tebroplasty-related, was cement extravasation (18.7%, 67/358 patients) [8, 12, 
15]. Progression of primary cancer was reported in 8/57 patients (14%) [22, 
25], fracture (without vertebroplasty) occurred in 2/92 patients (2.2%) [15], 
nerve root block in 3/36 patients (8.3%) [29], pain outside the target vertebrae 
due to progression of the primary or other metastatic disease in 3/50 patients 
(6%), ruptured disk adjacent to the index vertebra in 1/50 patients (2%), neu-
ropathic pain in 1/50 patients (2%), and syncope in 1/50 patients (2%) [1]. 
Recurrent pain after 2 months occurred in 1/10 patients (10%) and newly de-
veloped pain after 2 months in 2/10 patients (20%) [26]. 
Only one study did not report any procedure-unrelated adverse events [4]. 
C0002 – Are the harms related to dosage or frequency  
of applying radiofrequency ablation? 
No evidence was found to answer the research question. 
C0004 – How does the frequency or severity of harms change  
over time or in different settings? 
No evidence was found to answer the research question. 
C0005 – What are the susceptible patient groups that are more likely  
to be harmed through the use of radiofrequency ablation? 
No evidence was found to answer the research question. 
C0007 – Is radiofrequency ablation associated  
with user-dependent harms? 
No evidence was found to answer the research question. 
 
Investments and tools required 
B0010 – What kind of data/records and/or registry is needed  
to monitor the use of radiofrequency ablation? 
No evidence was found to answer the research question. 
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7 Quality of evidence 
The strength of evidence was rated according to GRADE (Grading of Recom-
mendations Assessment, Development and Evaluation) scheme [14] for each 
endpoint individually. Each study was rated by two independent researchers. 
In case of disagreement a third researcher was involved to solve the differ-
ence. A more detailed list of criteria applied can be found in the recommen-
dations of the GRADE Working Group [14]. 
GRADE uses four categories to rank the strength of evidence: 
 High = We are very confident that the true effect lies close to that  
of the estimate of the effect;  
 Moderate = We are moderately confident in the effect estimate:  
the true effect is likely to be close to the estimate of the effect, but 
there is a possibility that it is substantially different;  
 Low = Our confidence in the effect estimate is limited: the true effect 
may be substantially different from the estimate of the effect;  
 Very low = Evidence either is unavailable or does not permit  
a conclusion. 
The ranking according to the GRADE scheme for the research question can 
be found in Table 7-1. 
The strength of evidence on clinical effectiveness of RFA for metastatic spi-
nal lesions could not be assessed due to the lack of trials with a comparative 
treatment arm (study design). 
Overall, the strength of evidence for the safety of RFA for metastatic spinal 
lesions is very low. 
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Table 7-1: Evidence profile: efficacy and safety of radiofrequency ablation for metastatic spinal lesions 
No of studies/ 
patients Study Design Estimate of effect Study limitations Inconsistency Indirectness 
Other modifying 
factors 
Strength of 
evidence 
Efficacy 
Pain relief 
No data5 
Functional status 
No data
5
 
Health related quality of life (HRQoL) 
No data
5
 
Safety 
Overall complications 
4/112 Prospective single arm studies 20/112 (17.9%); Range: 19.4-40% Serious limitations (-1)6 0 Direct Imprecise data (-1)7 Very low 
5/4718 Retrospective single arm studies 58/471 (12.3%); Range: 4.3-21.9% Serious limitations (-1)
6
 0 Direct Imprecise data (-1)9 Very low 
Major complications (procedure-related) * 
4/112 Prospective single arm studies 0 Serious limitations (-1)
6
 0 Direct Imprecise data (-1)
7
 Very low 
5/471
8
 Retrospective single arm studies 0 Serious limitations (-1)
6
 0 Direct Imprecise data (-1)
9
 Very low 
Adverse events (procedure-related) 
4/112 Prospective single arm studies 5/112 (4.5%); Range: 10-11.1% Serious limitations (-1)
6
 0 Direct Imprecise data (-1)
7
 Very low 
5/471
8
 Retrospective single arm studies 11/471 (2.3%); Range: 0-9.8% Serious limitations (-1)
6
 0 Direct Imprecise data (-1)
9
 Very low 
Adverse events (not procedure-related) 
4/112 Prospective single arm studies 15/112 (13.4%); Range: 8.3-30% Serious limitations (-1)
6
 0 Direct Imprecise data (-1)
7
 Very low 
5/471
8
 Retrospective single arm studies 74/471 (15.7%); Range: 4.3-73% Serious limitations (-1)
6
 0 Direct Imprecise data (-1)
9
 Very low 
Nomenclature for GRADE table: 
Limitations: 0: no limitations or no serious limitations; -1: serious limitations 
Inconsistency: NA: Not applicable (only one trial); 0: no important inconsistency; -1: important inconsistency 
Indirectness: 0: direct, no uncertainty, -1: some uncertainty, -2 major uncertainty 
Other modifying factors: publication bias likely (-1), imprecise data (-1), strong or very strong association (+1 or +2), dose-response gradient (+1), Plausible confounding (+1) 
* None of the included studies reported any serious adverse events related to the procedure. 
                                                             
5 Due to the lack of a controlled group, no data on efficacy outcomes can be compared and synthesized. 
6 No control group. 
7 Small numbers of patients in included studies. 
8 72 patients of [4] may already be included in another retrospective study [15] . 
9 Overlap of patients in two studies. 
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8 Discussion 
Vertebral metastatic lesions are difficult-to-treat entities that most frequently 
affect patients who are suffering from breast, lung, or prostate cancer. Verte-
bral metastases are most commonly associated with (progressive) pain and se-
verely reduced HRQoL of affected patients. Untreated or progressing bone 
lesions can lead to pathological fractures and spinal instability, hypercalcemia 
or spinal cord compression. For a variety of patients, RFA is performed as a 
palliative therapy, especially for multimorbid elderly patients. Hence, RFA 
is performed in patients with metastatic spinal lesions primarily as a pallia-
tive pain therapy [1, 2, 8]. Currently, available evidence focusses on the fea-
sibility and safety of radiofrequency ablation as a palliative pain treatment. 
The aim of this report was to assess the clinical effectiveness and safety of 
RFA (with/without vertebroplasty or other add-on therapies) compared to an-
other or no treatment. 
 
Interpretation of the findings 
We identified 9 single-arm studies (4 prospective and 5 retrospective stud-
ies) for assessing the clinical effectiveness and safety of radiofrequency abla-
tion for metastatic spinal lesions. A total of 583 patients were enrolled in the 
included studies. 
Our systematic search was not limited to a specific study design or time pe-
riod. Retrospective studies had to include more than 30 patients diseased by 
vertebral metastases. Across all studies, a variety of ablation systems were 
used, the most commonly used was the STAR® Tumor Ablation System. All of 
the identified studies included patients with vertebral metastases suffering 
from severe pain. 
In terms of clinical effectiveness, we could not identify any controlled trials to 
assess the efficacy of RFA due to the lack of trials with a comparative treat-
ment arm (study design; no robust evidence). Nevertheless, four prospective 
studies provided outcomes on the clinical effectiveness of RFA. Eligible pa-
tients of these studies had painful vertebral metastases and were unrespon-
sive to previous treatments (e.g. analgesics, radiation, or chemotherapy). Other 
inclusion criteria were absence of neurological deficits, pain increase during 
movement, intervertebral tumour spread, and risk of paraplegia or fracture. 
Because the inclusion criteria differed slightly between studies, the determi-
nation of the best time for initiation of the treatment is difficult. 
Scores that measured pain (measured in all studies), HRQoL (reported in 2 
studies), and functional status (reported only in 1 study) were improved with 
the treatment of RFA (and vertebroplasty). All these changes were statisti-
cally significant in studies reporting on these outcomes. None of the studies 
reported changes on patient satisfaction with the treatment. 
In one study, no recurrence of vertebral metastases was reported during a 
mean follow-up period of 20.4 months [22]. However, other studies did not 
report on this outcome. Data on mortality during the follow-up periods was 
assessed in two studies. Because RFA is a palliative treatment life-prolong-
ing effects are not the primary aim of this technology and were not assessed 
in the studies. 
WS-Metastasen 
schwierig zu behandeln 
& assoziiert mit 
Schmerzen und 
Verminderung der 
Lebensqualität 
 
RFA meist als palliative 
Schmerzbehandlung 
durchgeführt 
9 Einzelarm-Studien 
eingeschlossen  
(4 prospektiv &  
5 retrospektiv)  
mit insgesamt  
583 PatientInnen 
keine robuste Evidenz 
für klinische 
Wirksamkeit; 
4 prospektive Studien: 
statistisch signifikante 
Verbesserungen in 
Schmerzen, 
Lebensqualität und 
funktionellem Status 
mit RFA (und 
Vertebroplastie) 
 
keine Evidenz  
zu allgemeiner 
Verbesserung oder 
Therapiezufriedenheit 
RFA wirkt sich nicht  
auf Verbesserung der 
Überlebensrate aus,  
da palliative Therapie 
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In terms of safety, all of the 9 included studies reported complications, how-
ever, no major complications occurred in any of the studies. Hence, major 
complications may be rare and may only be determined in studies with larg-
er patient samples or study registries. 
The overall complication rates were similar in all but two studies [12, 26]. 
This might be related to different follow-up periods and the stage of the dis-
ease. Procedure-related adverse events occurred in 5.6-16.6% of the patients 
across studies. The rates of adverse events that were not RFA-related (but ver-
tebroplasty-related) ranged from 4.3-73% across all studies (most frequently 
reported adverse event was cement extravasation). These may be associated 
with the treatment near the spinal cord and are, therefore, of a particular con-
cern. 
All of the included studies performed vertebroplasty treatment following RFA 
in most of the patients; if the destroyed tumour caused instability of the bone 
structure and a risk of fracture. Hence, vertebroplasty seems to offer a sup-
portive treatment option following RFA in patients with vertebral metastases 
at the risk for fracture. Nevertheless, vertebroplasty might also be a confound-
er of the post-interventional pain evaluation. 
According to included studies, adjuvant therapies, such as radiation or chem-
otherapy, are not postponed due to RFA and can be performed continuously 
as a therapy for primary cancers [4, 8]. 
 
Quality of Evidence 
Overall, the strength of evidence on clinical effectiveness cannot be determined. 
The strength of evidence is “very low” for safety outcomes. The strength of 
evidence was mainly downgraded due to missing data of control groups and 
overlap of patients in two studies. Most of the effectiveness outcomes were 
patient reported, hence subject to a high risk of bias. 
A major concern of most of the identified prospective studies is the low num-
ber of included patients. For instance, one study included only 10 patients. 
In order to identify rare complications, low patient numbers are insufficient. 
Two studies had a very short follow-up period of 2-4 weeks. Yet, only one 
study had a follow-up of 60 months. Therefore, reliable data of long-term safe-
ty and efficacy outcomes are missing. However, data collection is extremely 
difficult because long-term follow-up is challenging in patients with metastat-
ic spinal lesions due to high morbidity and mortality rates. 
Two studies were conducted in multiple centres [1, 15]. Four studies [4, 8, 
12, 15] were most likely reporting on the same cohort as studies that we con-
sequently excluded due to that fact [5, 20, 21, 34, 35]. It is probable that [4] 
included patients from [15], but only those patients with a VAS pain score of 
>4. This may distort the effect of RFA treatment. 
Eligibility criteria were unclear in 3 studies [8, 12, 15] and non-consecutive 
patient recruitment was performed in 3 retrospective studies [4, 15, 25]. Three 
studies were included at first, but excluded after data extraction because too 
few patients with vertebral metastases were included [3, 6, 23]. Two of the 
studies were sponsored by manufacturers [1, 12], whereby the other studies 
did not report direct study sponsoring. 
alle 9 Studien berichten 
von unerwünschten 
Ereignissen 
keine schwerwiegenden 
Komplikationen 
Vertebroplastie häufig 
im Anschluss an RFA  
Zementaustritt 
häufigstes 
unerwünschtes Ereignis 
Chemotherapie, 
Bestrahlung etc. kann 
ohne Unterbrechung 
fortgesetzt werden 
Stärke der Evidenz für 
klinische Wirksamkeit 
nicht bestimmbar; 
sehr geringe Stärke  
der Evidenz für 
Sicherheitsendpunkte 
 
relativ kleine Fallzahlen 
in prospektiven Studien 
relativ kurze Nach-
beobachtungszeiträume 
(palliativ) 
Mehrfachberichte  
von PatientInnen in  
2 Studien möglich 
 
zahlreiche Subanalysen 
zu Studien 
(ausgeschlossen); 
unklare 
Einschlusskriterien, 
nicht-konsekutive 
Rekrutierung 
Discussion 
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The utilised RFA systems and interventions differed slightly between the in-
dividual studies. For instance, patients were treated with additional therapies 
before or following RFA such as radiation therapy or analgesics. It is possi-
ble that these therapies and the different RFA systems have had an impact 
on the recorded outcomes of the studies (such as pain and HRQoL). 
Nevertheless, the included studies in this review show that image-guided RFA 
with or without vertebroplasty might be a feasible and safe technique for pa-
tients with painful metastatic spinal lesions. Particularly so because there were 
no serious complications reported. No therapy means intolerable pain for the 
patient. If other treatments are contraindicated, RFA (in combination with 
vertebroplasty) may be an effective treatment for pain reduction on the basis 
of the included studies. 
Due to the palliative course of the disease and the limited life expectancy of 
patients with painful metastatic spinal lesions, an effective and safe therapy, 
such as RFA, to improve pain relief and HRQoL that can also be performed 
on an outpatient setting might be beneficial. 
 
Upcoming evidence 
We identified 3 ongoing studies: one study is a phase II clinical trial evaluat-
ing the efficacy of thermal ablation in combination with spinal stereotactic 
radiosurgery with the primary outcome of the rate of local tumour control 
(estimated completion date August 2022) (NCT02713269). 
Another one of the ongoing studies is listed as “STAR Tumour Ablation Reg-
istry” (observational study) with the estimated completion date in August 2018 
and with pain relief as the primary outcome (NCT02419703). 
We also identified one ongoing randomized parallel controlled trial, which 
analyses the effect of analgesia and tumour local control rate with the appli-
cation of radiofrequency ablation combined with vertebroplasty compared to 
vertebroplasty only for vertebral metastases (ChiCTR-INR-16010135). This 
trial might show effects with a higher quality of evidence on pain and com-
plications. 
Furthermore, we found two “ongoing” interventional studies that were ter-
minated because of difficulties with enrolling patients (NCT02225223 (n=36) 
& NCT02081053 (n=30)). Their primary completion date was October and 
November 2016, but no data was published. 
 
Limitations 
First of all, no RCT’s or controlled trials were found in our literature search. 
Therefore, we decided to include prospective and retrospective observational 
studies and case-series for assessing the clinical effectiveness and safety of 
RFA. We only considered retrospective case-series with a patient cut-off of at 
least 30 patients treated for vertebral metastases. Thus, we excluded case-
series with less than 30 patients. Presumably, there were numerous retrospec-
tive studies with less than 30 patients that were not included. It may be pos-
sible that we excluded studies that may have reported results of e.g., differ-
ent complications or other products. Since we included single-arm prospec-
tive and retrospective studies, the sources of error due to confounding and 
bias are high. 
Interventionen in 
Studien wichen leicht 
voneinander ab  
 könnte Einfluss  
auf Ergebnisse haben 
eingeschlossene Studien 
zeigen, dass RFA  
(in Kombination mit 
Vertebroplastie) eine 
sichere Intervention  
für PatientInnen mit 
schmerzhaften  
WS-Metastasen ist 
 
bei Kontraindikation  
mit anderen Therapien 
scheint RFA effektive 
Schmerzbehandlung  
zu sein 
3 laufende Studien,  
eine davon ist als 
Registerstudie gelistet 
mögliche Limitationen: 
 keine RCT’s verfügbar, 
deshalb pro- und 
retrospektive Studien 
eingeschlossen; 
 nur Einzelarm-Studien 
 Bias-Risiko hoch 
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Another limitation of this systematic review is that pain medication usage 
was not collected in the extraction table, but also not reported in all of the in-
cluded studies and might be a possible confounder for the decrease in pain. 
An additional limitation is that all the studies rely on subjective reported out-
comes. For example, subjective pain scores may be confounded by analgesic 
medication. In addition, most of the RFA treatments were followed by ver-
tebroplasty that is likely to be a possible confounder on post-interventional 
pain assessment. 
 
Conclusion 
In patients with metastatic spinal lesions who are unresponsive to conven-
tional therapies, such as radiation or chemotherapy, who have contraindica-
tions to such therapies, or who are vulnerable for tumour progression, RFA 
(most commonly used in combination with vertebroplasty) may be a safe and 
effective therapy to palliate pain. 
Further evaluation of RFA (in combination with vertebroplasty) for longer-
term clinical efficacy and complication rates, in particular compared with 
traditional therapies, e.g., radiation, may be useful. The recommendation for 
the intervention cannot be maintained otherwise. 
Because there are various operation techniques (e.g., differences in RFA-tech-
niques, vertebroplasty following RFA etc.), further studies should be conduct-
ed to help determine the exact patient group that would benefit most from the 
intervention. Study registries may serve this purpose well. 
 
 
 
 Einsatz von 
Schmerzmitteln 
wurde nicht in 
Extraktionen erfasst 
 möglicher 
Confounder; 
 Studien basieren  
auf subjektiven 
Angaben 
RFA könnte eine  
sichere und wirksame 
Schmerzbehandlung  
für PatientInnen mit 
WS-Metastasen sein 
diverse Therapien 
verfügbar; weitere 
Evaluierung wichtig, um 
Empfehlung aufrecht zu 
erhalten 
 
weitere Studien bzw. 
Studienregister sind 
notwendig, um jene 
PatientInnen zu 
erreichen, die am 
meisten von der 
Intervention profitieren 
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9 Recommendation 
In Table 9-1 the scheme for recommendations is displayed and  
the according choice is highlighted. 
Table 9-1: Evidence based recommendations 
 The inclusion in the catalogue of benefits is recommended.  
X The inclusion in the catalogue of benefits is recommended with restrictions. 
 The inclusion in the catalogue of benefits is currently not recommended. 
 The inclusion in the catalogue of benefits is not recommended. 
 
Reasoning: 
The natural course of metastatic spinal lesions is fatal with intolerable pain. 
Thus, on ethical grounds, every therapy providing pain relief and causes no 
major complications may be justified. The current evidence indicates that the 
assessed technology RFA is, under certain conditions, effective and safe for 
the treatment of painful metastatic spinal lesions. The intervention should 
only be performed in specialized centres and, as possible, with registry acqui-
sition for potential and rare adverse events. 
Due to the low quality of evidence of the included studies, we recommend 
radiofrequency ablation for metastatic spinal lesions with restrictions. The 
technology might be used for patients with metastatic spinal lesions as palli-
ative pain treatment in whom alternative treatments do not achieve sufficient 
effect or are contraindicated. 
A re-evaluation is recommended after 2021 because of relevant ongoing stud-
ies, including a registry study that may provide new evidence of the technol-
ogy (see Appendix Table A-6). 
 
 
Empfehlungsschema 
Empfehlung unter 
bestimmten 
Bedingungen  
palliative 
Schmerzbehandlung in 
spezialisierten Zentren 
(möglichst mit 
Registererfassung  
für unerwünschte 
Ereignisse) 
Re-Evaluierung nach 
2021 empfohlen 
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Appendix 
Evidence tables of individual studies included for clinical effectiveness and safety 
Table A-1: RFA: Results from prospective studies 
Author, year Bagla, 2016 [1] Gazis, 2014 [29] Nakatsuka, 2009 [26] Proschek, 2009 [22] 
Country USA Germany Japan Germany 
Sponsor DFINE Inc. NR NR NR 
Intervention/Product RFA 
STAR Tumor Ablation System 
(DFine Inc., USA) 
Co-Intervention:  
vertebroplasty (47 pts) 
RFA 
CelonLab Power and Celon Aquaflow III 
(Celon AG Medical Instruments, 
Germany) 
RFA 
Cool-tip RF Ablation System 
(Valleylab, USA) 
Co-Intervention:  
vertebroplasty (n=6) 
RFA (group 1) 
RFA & vertebroplasty (group 2) 
Celon Pro Surge & CelonPOWER 
System (Celon AG Medical 
Instruments, Germany) 
Co-Intervention:  
vertebroplasty (n=8/Group 2) 
Study design Multicentre single-arm 
prospective study 
(8 sites, USA) 
Single-centre prospective cohort study 
(Retrospective analysis) 
Single-centre prospective study Single-centre prospective  
pilot-study 
Setting (e.g. outpatient, 
university hospital etc.) 
Hospital University hospital University hospital University hospital 
(treated on an outpatient basis) 
Number of pts 50 36 10 16 (8 vs. 8) 
Inclusion criteria  ≥18 years; 
 Painful vertebral body 
metastasis (VBM) in at least 
one thoracolumbar vertebra 
with the pain concordant to 
the metastatic lesion on 
cross-sectional imaging; 
 Considered candidates for 
spinal tumor ablation by the 
operating physician; 
 Severe local tumor pain insufficiently 
responsive to opiates and other 
analgesics; 
 Disease progression despite previous 
surgery, maximal chemotherapy, 
maximal radiation and hormone 
therapy, lack of or highly invasive 
surgical option; 
 Intervertebral tumor spread; 
 Risk of paraplegia/fracture because of 
tumor progression; 
 Locomotor disability because of local 
tumor process, and osteolytic/mixed 
metastases with palliative intention; 
 Painful spinal tumor 
refractory to previous medical 
treatment with radiation 
therapy and/or chemotherapy; 
 Distance of 1 cm or less 
between the spinal tumor 
invaded the posterior cortex 
of the vertebral body or 
pedicle and spinal cord; 
 Pain (refractory to previous 
treatment), improvement of 
quality of life as well as 
imminent fracture or 
instability of the bone due to 
rapid tumor growth; 
 Absence of neurological 
deficits; 
 Increase of pain during 
movement or excessive 
stress; 
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Author, year Bagla, 2016 [1] Gazis, 2014 [29] Nakatsuka, 2009 [26] Proschek, 2009 [22] 
Exclusion criteria  VBM in cervical vertebrae 
and posterior tumor 
extension with cord 
compression; 
 Contraindication with heart 
pacemakers, or other 
electronic device implants; 
 Contraindicated in vertebral 
body levels C1-7; 
 Presence of intradural and 
intramedullary tumors; 
 Risk of bleeding (acetylsalicylic acid, 
anticoagulants); 
 Acute general infections, local 
infections in the target zone; 
 Allergies against periinterventional 
applied drugs; 
 Zubrod performance status  
of 4; 
 Symptomatic spinal cord 
compression; 
 Platelet count of less than 
50,000/µL or an international 
normalized ratio greater  
than 1.5; 
 Vertebral fractures; 
 Radicular neurological 
symptoms; 
 Coagulation disturbances; 
 Rheumatic diseases; 
 Allergy to local anesthesia; 
 Pregnancy; 
 Infections (e.g. spondylitis, 
spondylodiscitis); 
Mean age of patients, yrs (SD) 61, range 23-83 (13) 67.8, range 40-84 61, range 52-78 (13) 59.5, range 52-69 
Sex, female vs. male (% female) 24 vs. 26 (48)* 12 vs. 24 (33.3)* 4 vs. 6 (40) 16 vs. 0 (100) 
Total vertebra treated metastatic 
bodies/lesions (mean per patient) 
69 (1.4) 39 10 16 pts 
Mean duration of intervention, 
min (range) 
Ablation time/VB: 6.7 min 22.6 min (12-43) 8.3 (5-12) NR 
Follow-up (months) 3 NR 4.5, range 2.7-7.1 (SD 1.3) 20.4, range 8-36 
Follow-up time periods Pre- & post-treatment; 
3 days 
1 week 
1 mo 
3 mo 
24-48 hours post-treatment 1 week 
every 4 weeks until death 
NR 
Loss to follow-up, n (%) 16 (32%), at 3 mo NR 0 NR 
Pre-interventional procedure 
(e.g. MRI, CT), (n) 
Physical examination; review of 
the patients’ imaging 
MRI (36) Routine physical examination, 
laboratory tests, CT and MRI 
CT scans, MRI and X-ray 
Post-interventional  
procedure (n) 
No additional therapy  
(42 pts, 84%) 
Radiation therapy (2 pts, 4%) 
NR (6 pts, 12%) 
MRI (36) - - 
Outcomes 
Efficacy 
Pain (increase of pain relief) NPRS10 NR VAS11 VAS
11
 
No significant group differences. 
 Pre-interventional 5.9 NR 7.5 (SD 2.7) Group 1: 7.9, range 6-10 
Group 2: 7.6, range 7-10 
                                                             
10 Pain was measured on a Numerical Pain Rating Scale (NPRS). NPRS ranges from 0 (no pain) to 10 (worst possible pain). 
11 Pain was measured on a Visual Analogue Scale (VAS). VAS ranges from 0 (no pain) to 10 (worst possible pain). 
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Author, year Bagla, 2016 [1] Gazis, 2014 [29] Nakatsuka, 2009 [26] Proschek, 2009 [22] 
 Post-interventional 3.7 (decrease of 2.2), s.s. Pain reduction in 19 cases (52.8%) 
No change in 13 cases (36.1%) 
NR Group 1: 5.5, range 3-8  
(decrease of 2.4), s.s. 
Group 2: 5, range 3-7  
(decrease of 2.6), s.s. 
 Short term (<6 weeks) 1 mo (n=40): 2.6  
(decrease of 3.3), s.s. 
NR 1 week: 2.7 (SD 2)  
(decrease of 4.8), s.s. 
NR 
 Mid term  
(>6 weeks - ≤6 months) 
3 mo (n=34): 2.1  
(decrease of 3.8), s.s. 
NR In 90% of pts pain relief lasted 
during survival period (9/10) 
NR 
 Longer term (>6 months) - NR - 15-36 mo post: 
Group 1: 4, range 2-6  
(decrease of 3.9), s.s. 
Group 2: 3.5, range 1-5  
(decrease of 4.1), s.s. 
Functional status Back-related disability 
(MODI)12 
NR NR NR 
 Pre-interventional 52.9% NR NR NR 
 Post-interventional NR NR NR NR 
 Short term (≤6 weeks) 1 mo (n=40): 40.0%  
(change to baseline: 12.9%), s.s. 
NR NR NR 
 Mid term (>6 weeks  
up to ≤6 months) 
3 mo (n=34): 37.0%  
(change to baseline: 15.9%), s.s. 
NR NR NR 
 Longer term (>6 months) - NR NR NR 
Health-related quality of life 
(HRQoL) 
FACT-G7
4
 
FACT-BP13 
NR NR QoL Oswestry Index 
No significant group differences. 
 Pre-interventional FACT-G7 
11.0 
FACT-BP 
22.6 
NR NR Group 1: 64%, range 38-84% 
Group 2: 66%, range 39-86% 
 Post-interventional NR NR NR Group 1: 34%, range 28-38% 
(improvement 30%) 
Group 2: 36%, range 31-39% 
(improvement 30%) 
                                                             
12 The Modified Oswestry Disability Index (MODI) ratings and corresponding categories are 0–20 (minimal disability), 21–40 (moderate disability), 41–60 (severe disability),  
61–80 (crippled) and 81–100% (bed bound). 
13 The FACT-G7 is abbreviated to seven evaluable questions and considered a rapid version of the FACT-G which has 27 questions. FACT-BP is specifically designed for use in 
cancer patients with bone pain and contains 15 evaluable questions. Higher scores are interpreted as greater patient quality of life, and lower scores are interpreted as lower patient 
quality of life. FACT-G7 has a scale from 0 to 28 and FACT-BP 0–60. 
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Author, year Bagla, 2016 [1] Gazis, 2014 [29] Nakatsuka, 2009 [26] Proschek, 2009 [22] 
 Short term (≤6 weeks) FACT-G7 
1 mo (n=40): 15.8  
(change to baseline: 4.8), s.s. 
FACT-BP 
1 mo (n=40): 37.3  
(change to baseline: 14.7), s.s. 
NR NR NR 
 Mid term (>6 weeks  
up to ≤6 months) 
FACT-G7 
3 mo (n=34): 16.2  
(change to baseline: 5.2), s.s. 
FACT-BP 
3 mo (n=34): 38.9  
(change to baseline: 16.3), s.s. 
NR NR 3-6 mo post: 
Group 1: 33%, range 23-38% 
(improvement 31%) 
Group 2: NR 
 Longer term (>6 months) - NR NR 15-36 mo post: 
Group 1: NR 
Group 2: 35%, range 26-38% 
(improvement 31%) 
Satisfaction with treatment NR NR NR NR 
Recurrence of vertebral 
metastases, n (%), (local relapse) 
NR NR NR 0 
Mortality, n (%) 5 (10) NR 10 (100)b NR 
Safety 
Overall complications, n (%) 6 (12)* 7 (19.4)* 4 (40)* 3 (18.7)* 
 Major complications (n)a - - -  
 Adverse events (not 
procedure related), n (%) 
6 (12) 
 Pain outside the target 
vertebrae due to progression 
of the primary or other 
metastatic disease (3), 
 ruptured disk (1) adjacent  
to the index vertebra, 
 neuropathic pain (1) and 
syncope (1) 
3 (8.3) 
 Nerve root block (3) 
3 (30) 
 Recurrent pain after 2 mo (1), 
 newly developed pain after  
2 mo (2) 
3 (18.7) 
 Progress of primary tumor (3) 
 Adverse events (procedure 
related), n (%) 
- 4 (11.1) 
 Worsening of pain (4) 
1 (10) 
 Transient nerve injury (1) 
- 
Abbreviations: FACT-G7 Functional Assessment of Cancer Therapy-General 7; FACT-BP Functional Assessment of Cancer Therapy Quality of Life Measurement in patients with bone pain; 
MODI Modified Oswestry Disability Index; NPRS Numerical Pain Rating Scale; NR not reported; n.s. not significant; RFA radiofrequency ablation; s.s. statistically significant;  
VAS visual analogue scale; VBM vertebral body metastases; yrs years; 
a The definition of a major complication was an event that resulted in substantial morbidity or disability, an increase in the level of care, admission to the hospital, or substantial prolongation  
of the hospital stay (Society of Interventional Radiology classifications C-E). 
b All patients died due to the follow-up until death.  * own calculations 
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Table A-2: RFA: Results from retrospective studies 
Author, year Anchala, 2014[15]
a
 Gevargez, 2008 [25]14 Wallace, 2015 [4]
b
 
Country USA Germany USA 
Sponsor NR15 NR NR
9
 
Intervention/Product RFA 
STAR Tumor Ablation System  
(DFine Inc., USA) 
Co-intervention:  
vertebroplasty (88) 
RFA 
Radionics System & RITA Medical System  
(Radionics Inc., USA &  
RITA Medical System Inc., USA) 
Co-Intervention: vertebroplasty (n=22) 
RFA 
STAR Tumor Ablation System  
(DFine Inc., USA) 
Co-intervention:  
vertebroplasty (95% of ablations) 
Study design Multicentre retrospective study Single-centre retrospective study Single-centre retrospective study 
Setting (e.g. outpatient,  
university hospital etc.) 
University hospital University hospital University hospital 
Number of pts 92 41 72 
Inclusion criteria NR  Severe local tumor pain insufficiently 
responsive to opiates and other analgesics; 
 Disease progression despite previous 
surgery, maximal chemotherapy, maximal 
radiation, and hormone therapy; 
 Lack of or highlyinvasive surgical option; 
 Lack of other therapeutic options; 
 Metastases in bone or spine; 
 Intravertebral tumor spread; 
 Risk of paraplegia or fracture because  
of tumor progression; 
 Osteolytic and mixed metastases; 
 Pain limiting quality-of-life and 
uncontrolled with opioid analgesics  
(≥4 NRS); 
 Tumor within 1 cm of the spinal cord or 
nerves was no contraindication for 
RFA; 
Exclusion criteria NR  Progressive metastases (involving more than 
three organs) with reduced life expectancy; 
 Poor general condition; 
 Intradural and intramedullary tumors; 
 Risk of bleeding (acetylsalicylic acid, 
anticoagulants); 
 Osteoblastic metastases; 
 Osteoblastic metastases, associated 
with pathologic compression fracture 
with spinal instability, or causing 
metastatic spinal cord compression; 
                                                             
14 The number of patients is different at each time point of the assessment due to a number of incomplete questionnaires. 
15 Conflict of Interest: DFine Inc. (speaker panel, consultant, lab instructor). 
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Author, year Anchala, 2014[15]
a
 Gevargez, 2008 [25]14 Wallace, 2015 [4]
b
 
Mean age of patients, yrs (SD) NR 62.7, range 46-82 (SD 9) 68.4 (18.8) 
Sex, female vs. male (% female) NR 16 vs. 25 (39) 44 vs. 28 (61) 
Total vertebra treated metastatic 
bodies/lesions (mean per patient) 
128 RFA/pts: 1.8, range 1-6 (SD 1.1) 110 
Mean duration of intervention, min (range) At largest centre: 55-653 sec  
(average 361 sec) 
NR 8 min 32 sec (4 min 49 sec) 
Follow-up (months) 6 >6 (278-617 days) 1 
Follow-up time periods 1 week 
1 mo 
6 mo 
6 weeks 
6 mo 
>6 mo 
1 week 
4 weeks 
Loss to follow-up, n (%) 9 at 1 month (9.8) 25 (61) 8 (11.1) 
Pre-interventional procedure (e.g. MRI, CT) MRI neurological examination, hematology/clinical 
chemistry, MRT and CT 
MRI, PET-CT, CT 
Post-interventional procedure (n) MRI - NR 
Outcomes 
Efficacy 
Pain (increase of pain relief) VAS16 VAS
16
 NRS17 
 Pre-treatment 7.51 (SD 2.46), (n=92) NR 8 (SD 1.9), (n=64) 
 Post-interventional NR NR NR 
 Short term (<6 weeks) 1 week (n=56): 1.73 (SD 2.28), s.s. 
1 mo (n=83): 2.25 (SD 2.44), s.s. 
6 weeks: relative reduction 36.2% (n=26), s.s. 1 week (n=64): 3.9 (SD 3), s.s. 
4 weeks (n=58): 2.9 (3), s.s. 
 Mid term (>6 weeks - ≤6 months) 6 mo (n=9): 1.75 (SD 2.62), s.s. 6 mo: relative reduction 50% (n=19), s.s. - 
 Longer term (>6 months) - >6 mo: relative reduction 50% (n=14), s.s. - 
Functional status NR Overall functional avtivity PDI scores18 NR 
 Post-interventional NR - NR 
 Short term (≤6 weeks) NR 6 weeks: relative improvement 8% (n=24) NR 
 Mid term (>6 weeks up to ≤6 months) NR 6 mo: relative improvement 4% (n=21) NR 
                                                             
16 Pain was measured on a Visual Analogue Scale (VAS). VAS ranges from 0 (no pain) to 10 (worst possible pain). 
17 Numerical rating scale (NRS) ranges from 0 (no pain) to 10 (worst possible pain). 
18 The Pain Disability Index (PDI) is a 10-Item scale: 0 = no interference, 10 = total interference. 
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Author, year Anchala, 2014[15]
a
 Gevargez, 2008 [25]14 Wallace, 2015 [4]
b
 
 Longer term (>6 months) NR >6 mo: relative improvement 10% (n=15) NR 
Health-related quality of life (HRQoL) NR Karnofsky index19 
“No changes in short, mid and longer term.” 
NR 
Satisfaction with treatment NR NR NR 
Recurrence of vertebral metastases, n (%) 
(local relapse) 
NR NR NR 
Mortality, n (%) NR NR 6 (9.4) 
Safety 
Overall complications, n (%) 4 (4.3)* 9 (22)* 4 (5.6)* 
 Major complications (n)c - - - 
 Adverse events (not procedure related), 
n (%) 
4 (4.3) 
 Fracture without cement 
augmentation (2), 
 cement extravasation (2) 
5 (12.2) 
 Tumor progression (5) 
- 
 Adverse events (procedure related),  
n (%) 
- 4 (9.8) 
 Increased pain and numbness (2), 
 unilateral monoradiculopathy (1), 
 “heavy legs” with paresthesia (1) 
4 (5.6) 
 Post-procedure radicular pain (4) 
Abbreviations: NRS Numerical Rating Scale; NR not reported; n.s. not significant; PDI Pain Disability Index; RFA radiofrequency ablation; s.s. statistically significant;  
VAS visual analogue scale; VBM vertebral body metastases; yrs years; 
a For sub analysis see references Hillen 2014 [34] and Greenwood 2015 [5]. 
b This study is also a sub analysis of Anchala 2014 [15]; (34 patients are already included in Anchala 2014). For further sub analysis see reference Wallace 2016 [35]. 
c The definition of a major complication was an event that resulted in substantial morbidity or disability, an increase in the level of care, admission to the hospital,  
or substantial prolongation of the hospital stay (Society of Interventional Radiology classifications C-E). 
* own calculations 
 
                                                             
19 There were no changes of the median percentage changes in the Karnofsky index at any time point indicating an overall stable general condition of the patients. 
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Table A-3: RFA: Results from retrospective studies (continued) 
Author, year Dabravolski, 2015 [8]
a
 Georgy, 2009 [12]
b
 
Country Germany USA 
Sponsor NR ArthroCare Corporation 
Intervention/Product RFA 
CAVITY SpineWand (ArthroCare Corporation, USA) 
Co-Intervention:  
vertebroplasty (229 pts); 
Dorsal percutaneous instrumentation (59 pts) 
Combination with chemotherapy & radiation (229 pts); 
RFA 
CAVITY SpineWand (ArthroCare Corporation, USA) 
Co-Intervention:  
vertebroplasty (37 pts) 
Study design Single-centre retrospective study20 Single-centre retrospective study
20
 
(consecutively treated & retrospectively reviewed) 
Setting (e.g. outpatient, university hospital etc.) University hospital NR 
Number of pts 250 (total) 
229 pts with spinal metastases 
37 
Inclusion criteria  Tumors and spinal metastases with destruction/osteolysis; 
 Fractures with instability and pain syndrome; 
NR 
Exclusion criteria NR NR 
Mean age of patients, yrs (SD) 65.5, range 31-92 69.6, range 34-89* 
Sex, female vs. male (% female) 156 vs. 94 (62.4) 21 vs. 16 (57) 
Total vertebra treated metastatic bodies/lesions  
(mean per patient) 
812 (229 pts) 44 
Mean duration of intervention, min (range) NR 
(only as combination: cavity & vertebro-/kyphoplasty:  
30-60 min (n=172)) 
NR 
Follow-up (months) 60 2-4 weeks 
Follow-up time periods 2 days 
2 weeks 
3 mo 
6 mo 
12 mo 
24 mo 
36 mo 
48 mo 
60 mo 
Pre-treatment 
2-4 weeks post-treatment 
Loss to follow-up, n (%) 7 (3.1) 9 (24%)*, VAS of 2-4 weeks 
Pre-interventional procedure (e.g. MRI, CT) MRI, X-ray, PET-CT, CT, whole body scintigraphy MRI (36), Bone scan (1) 
Post-interventional procedure (n) Every 6 mo: MRI, PET-CT, CT CT examination (37) 
                                                             
20 Judged as retrospective studies. 
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Author, year Dabravolski, 2015 [8]
a
 Georgy, 2009 [12]
b
 
Outcomes 
Efficacy 
Pain (increase of pain relief) VAS21 VAS
21
 
 Pre-treatment 7-10 NR 
 Post-interventional 0-3 (decrease by 6-8 points), s.s. NR 
 Short term (<6 weeks) NR 2-4 weeks: 25 pts (89.5%) reported pain relief 
 Mid term (>6 weeks - ≤6 months) NR - 
 Longer term (>6 months) NR - 
Functional status Improvement in mobilisation NR 
Health-related quality of life (HRQoL) Improvement in QoL NR 
Satisfaction with treatment Improvement in overall satisfaction NR 
Recurrence of vertebral metastases, n (%), (local relapse) 30 (13.1) NR 
 Post-interventional - NR 
 Short term (≤6 weeks) - NR 
 Mid term (>6 weeks up to ≤6 months) 6 mo: 4 (1.7%) NR 
 Longer term (>6 months) 1 yr: 8 (3.5%) 
2 yrs: 12 (5.2%) 
3 yrs: 6 (2.6%) 
4 yrs: - 
5 yrs: - 
NR 
Mortality, n (%) 188 (75.2) NR 
Safety 
Overall complications, n (%) 38 (16.6)* 30 (81.1)* 
 Major complications (n)c - NR 
 Adverse events (not procedure related), n (%) 38 (16.6) 
 Cement extravasation (38) 
27 (73) 
 Cement extravasation (27)* 
 Adverse events (procedure related), n (%) - 3 (8.1) 
 Epidural extravasation (2), 
 radicular symptoms (1) 
Abbreviations: NR not reported; n.s. not significant; RFA radiofrequency ablation; s.s. statistically significant; VAS visual analogue scale; VBM vertebral body metastases; yrs years; 
a For sub analysis see reference Dabravolski 2014 [20]. 
b For sub analysis see reference Georgy 2007 [21]. 
c The definition of a major complication was an event that resulted in substantial morbidity or disability, an increase in the level of care, admission to the hospital,  
or substantial prolongation of the hospital stay (Society of Interventional Radiology classifications C-E). 
* own calculations 
                                                             
21 Pain was measured on a Visual Analogue Scale (VAS). VAS ranges from 0 (no pain) to 10 (worst possible pain). 
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Risk of bias tables 
Internal validity of the included studies was judged by two independent researchers. In case of disagreement a third researcher was involved to solve the differences. 
A more detailed description of the criteria used to assess the internal validity of the individual study designs can be found in the Internal Manual of the LBI-HTA 
[36] and in the Guidelines of EUnetHTA [37, 38]. 
Table A-4: Risk of bias – study level (case series)22 
Study  
reference/ID 
Anchala, 
2014 [15] 
Bagla,  
2016 [1] 
Dabravolski, 
2015 [8] 
Gazis,  
2014 [29] 
Georgy, 
2009 [12] 
Gevargez, 
2008 [25] 
Nakatsuka, 
2009 [26] 
Proschek, 
2009 [22] 
Wallace, 
2015 [4] 
Study objective 
1. Is the hypothesis/aim/objective of the study stated 
clearly in the abstract, introduction, or methods section? 
Yes Yes No Yes Yes Yes Partial Yes Partial 
Study population 
2. Are the characteristics of the participants included  
in the study described? 
No Yes Yes Yes Yes Yes Yes Yes Yes 
3. Were the cases collected in more than one centre? Yes Yes Unclear No No No No No No 
4. Are the eligibility criteria (inclusion and exclusion criteria) 
for entry into the study explicit and appropriate? 
No Yes Partial Yes No Yes Yes Yes Yes 
5. Were participants recruited consecutively? No Unclear23 Unclear24 Unclear25 Yes Unclear26 Yes Unclear Unclear27 
6. Did participants enter the study at similar point  
in the disease? 
Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Intervention and co-intervention 
7. Was the intervention clearly described in the study? Yes Yes Yes Yes Yes Yes Yes Yes Yes 
8. Were additional interventions (co-interventions) clearly 
reported in the study? 
Partial Partial Yes Yes28 Yes Partial No Yes Partial 
                                                             
22 IHE Risk of Bias checklist, see [13]  
23 Patients were enrolled in an institutional review board approved study at eight sites in the USA between August 2013 and September 2014. 
24 Patients were enrolled between March 2008 and February 2014 with tumours and mainly spinal metastases. 
25 After providing written informed consent, 36 patients were treated for 39 lesions in the institution between November 2006 and April 2009. 
26 Patients with primary or secondary tumour involvement of the spine were treated between March 2000 and August 2002. 
27 Patients were selected and consecutively treated with RFA between April 2012 and July 2014. 
28 No additional intervention was performed. 
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Study  
reference/ID 
Anchala, 
2014 [15] 
Bagla,  
2016 [1] 
Dabravolski, 
2015 [8] 
Gazis,  
2014 [29] 
Georgy, 
2009 [12] 
Gevargez, 
2008 [25] 
Nakatsuka, 
2009 [26] 
Proschek, 
2009 [22] 
Wallace, 
2015 [4] 
Outcome measures 
19. Are the outcome measures clearly defined in the 
introduction or methods section? 
Yes Yes Partial Partial Partial Yes Partial Yes Yes 
10. Were relevant outcomes appropriately measured with 
objective and/or subjective methods? 
Yes Yes Partial Unclear Yes Yes Yes Yes Yes 
11. Were outcomes measured before and after 
intervention? 
Yes Yes Partial Yes Yes No Yes Yes Partial 
Statistical Analysis 
12. Were the statistical tests used to assess the relevant 
outcomes appropriate? 
Unclear Yes Unclear Unclear Unclear Yes Yes Yes Yes 
Results and Conclusions 
13. Was the length of follow-up reported? Yes Yes Yes Yes Yes Yes Yes Yes Yes 
14. Was the loss to follow-up reported? Yes Yes Yes No Unclear Yes Yes No Yes 
15. Does the study provide estimates of the random 
variability in the data analysis of relevant outcomes? 
Partial No No No No No Partial Partial Partial 
16. Are adverse events reported? Yes Yes Yes Yes Yes Yes Yes Yes Yes 
17. Are the conclusions of the study supported by results? Unclear Yes Yes Yes Yes Yes Unclear Partial Partial 
Competing interest and source of support 
18. Are both competing interest and source of support  
for the study reported? 
Partial Yes No No Yes No No No No 
Overall Risk of bias High Moderate High High Moderate Moderate High Moderate High 
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Applicability table 
Table A-5: Summary table characterising the applicability of a body of studies 
Domain Description of applicability of evidence 
Population All studies included patients with painful vertebral metastases. The studies included a total of  
583 patients. The mean age of included patients ranged 61-69.6 years. 
The inclusion criteria and the population in the studies seem to be in accordance with the intended 
patient population for the technology. 
Intervention Patients in the included studies were treated with different RFA-systems and the intervention  
was mainly performed in university hospitals and treated in an outpatient setting. 
In all studies, it was stated that most of the patients received vertebroplasty after RFA. 
Comparators There were no comparators. 
To date, there are no published studies in which RFA (in combination with vertebroplasty or other 
add-on therapies) are compared to other or no treatment. 
Outcomes The most frequently reported crucial outcomes were changes in pain and adverse events 
(procedure-related and not procedure-related). Other important outcomes, such as health-related 
quality of life, funtional status and satisfaction with treatment were only reported in some of the 
included studies. 
The outcomes on clinical effectiveness have shown subjective benefits from the treatment with 
RFA (in combination with vertebroplasty). For the safety assessment, no major complications 
were reported across studies. 
However, the presented data in the studies is limited, especially due to small sample sizes in 
prospective studies and short follow-up times (due to the palliative setting). Possible multiple-
reporting of study participants in different studies may also lead to imprecise data. 
Setting The intervention was performed under image-guiding and general anaesthaesia. Two of the 
studies were multi-centre studies carried out in the US. The other seven studies were single-centre 
studies conducted in the US (2), Japan (1), and Europe (4). All of the European studies were based 
in Germany. The studies were published between 2008 and 2016. 
The intervention was performed in University hospitals across studies, but in some it was  
reported that the intervention might also be performed in an outpatient setting because of its 
minimal-invasive procedure and short recovery time. 
The settings of the studies reflect the clinical setting in which the technology is intended to be 
used in an appropriate way. 
No applicability issues are expected from the geographical setting. 
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List of ongoing trials 
Table A-6: List of ongoing trials (radiofrequency ablation and metastatic spinal lesions) 
Source 
Identifier/ 
Trial name Patient population Intervention Comparison 
Primary 
Outcome 
Primary 
completion 
date Sponsor 
ClinicalTrials.
gov 
NCT02713269 
A Phase II Clinical Trial 
Evaluating the Efficacy  
of Combining Thermal 
Ablation and Spine 
Stereotactic Radiosurgery 
for Patients With Spine 
Metastases With 
Moderate to Severe 
Epidural Involvement 
Patients ≥ 18 years old; Histologic diagnosis of 
solid malignant tumor epidural spinal cord 
compression 1C, 2, or 3; vertebral body site 
located from T2-T12; <3 contiguous or 
discontiguous vertebral levels involved with 
metastasis in the spine; motor strength >/=4 
out of 5 in extremity or extremities affected by 
the level of the spinal cord compression; ECOG 
performance status </=2 or Karnofsky 
performance status (KPS) >/=50; life 
expectancy >3 months; inoperable disease 
because of patient refusal, neurosurgical 
evaluation, or other medical reasons 
Thermal Ablation 
Procedure, 
Stereotactic Spine 
Radiosurgery (SSRS) 
- Rate  
of local 
tumor 
control 
August 
2022 
M.D. Anderson 
Cancer Center, 
Medtronic 
ClinicalTrials.
gov 
NCT02419703 
The STAR™ Tumor 
Ablation Registry 
Male or female patients ≥22 years old; painful 
spinal metastatic lesions in thoracolumbar 
vertebrae (T1-L5) that will be treated with t-
RFA using the STAR™ Tumor Ablation System; 
signed informed consent 
Device: STAR™ Tumor 
Ablation System 
(Targeted-radiofrequency 
ablation (t-RFA) of painful 
metastatic tumor in the 
vertebral body) 
- Pain 
relief 
December 
2018 
DFINE Inc., 
Merit Medical 
Systems, Inc. 
ClinicalTrials.
gov 
NCT02225223 
Evaluation of Targeted 
Radiofrequency Ablation 
and Vertebral 
Augmentation Prior to or 
Following Radiation 
Therapy to Treat Painful 
Metastatic Vertebral 
Body Tumor(s) [The 
STARRT Study]29 
Male or female patients ≥ 18 years old; one to 
two painful vertebrae (T1-L5) with evidence of 
osteolytic or mixed lytic and blastic metastatic 
lesion by cross sectional imaging and pathologic 
fracture; Brief Pain Inventory (BPI) worst pain 
score of ≥ 4; life expectancy of ≥ 2 months 
Device: STAR™ Tumor 
Ablation System 
(Targeted-radiofrequency 
ablation (t-RFA)) 
Device: StabiliT® 
Vertebral Augmentation 
System (Radiofrequency-
targeted vertebral 
augmentation (RF-TVA)) 
- Pain 
relief 
October 
2016 
DFINE Inc., 
Merit Medical 
Systems, Inc. 
                                                             
29 This study has been terminated. (Difficulty Enrolling). 
https://clinicaltrials.gov/ct2/show/record/NCT02225223?term=radiofrequency+ablation+AND+metastatic+spinal+lesions&rank=1 
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Source 
Identifier/ 
Trial name Patient population Intervention Comparison 
Primary 
Outcome 
Primary 
completion 
date Sponsor 
ClinicalTrials.
gov 
NCT02081053 
A Prospective, Multicenter 
Clinical Study to Evaluate 
the Clinical Outcomes of 
Targeted Radiofrequency 
Ablation and Vertebral 
Augmentation to Treat 
Painful Metastatic 
Vertebral Body 
Tumor(s)30 
One to 2 painful vertebrae (T1-L5) with 
evidence of osteolytic metastatic lesion with 
known primary histology with pathologic 
fracture(s) at index vertebra by MRI;  
pain score ≥ 4 on the numerical rating pain 
scale; Life expectancy of ≥ 6 months 
Device: STAR™ Tumor 
Ablation System and 
StabiliT® Vertebral 
Augmentation System 
(Radiofrequency targeted 
radiofrequency ablation 
(t-RFA) and targeted 
vertebral augmentation 
(RF-TVA)) 
- Pain 
relief 
November 
2016 
DFINE Inc., 
Merit Medical 
Systems, Inc. 
WHO-ITCRP ChiCTR-INR-16010135 
The Medium-and Long-
Term Clinical Research of 
Radiofrequency Ablation 
Combined With Per-
cutaneous Vertebroplasty 
in Spine Metastases 
Male or female patients; meet the diagnostic 
critrea; moderate pain(VAS>3); aged over  
18 years; vertebral bone cortical continuity 
was intact; expected survival is more than  
3 months; informed consent 
Radiofrequency Ablation 
Combined With 
Percutaneous 
Vertebroplasty 
Percutaneous 
Vertebroplasty 
Pain September 
2021 
National Cancer 
Center/Cancer 
Hospital, Chinese 
Academy of 
Medical Sciences 
& Peking Union 
Medical College 
 
 
 
 
                                                             
30 This study has been terminated. (Difficulty Enrolling). 
https://clinicaltrials.gov/ct2/show/record/NCT02081053?term=radiofrequency+ablation+AND+metastatic+spinal+lesions&rank=2 
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Literature search strategies 
Search strategy for Cochrane 
Search Name: RFA for Spinal Metastases 
Search Date: 28.12.2016 
ID Search 
#1 radiofrequency near (ablati* or therap* or treatment* or intervention* or program* or procedure*)  
(Word variations have been searched) 
#2 radio-frequency near (ablati* or therap* or treatment* or intervention* or program* or procedure*)  
(Word variations have been searched) 
#3 MeSH descriptor: [Catheter Ablation] explode all trees 
#4 #1 or #2 or #3 
#5 MeSH descriptor: [Spinal Neoplasms] explode all trees 
#6 (neoplasm* or tumor* or tumour* or cancer* or carcinoma*) near (spine* or spinal or vertebra*)  
(Word variations have been searched) 
#7 #5 or #6 
#8 MeSH descriptor: [Neoplasm Metastasis] explode all trees 
#9 metasta* (Word variations have been searched) 
#10 #8 or #9 
#11 #7 and #10 
#12 (spine* or spinal or vertebra*) near metasta* (Word variations have been searched) 
#13 #11 or #12 
#14 #4 and #13 
Total: 5 Hits 
 
 
Search strategy for CRD (DARE, NHS-EED, HTA) 
#### RFA for Spinal Metastases 
Search Date: 28.12.2016 
1 (radiofrequency NEAR (ablati* OR therap* OR treatment* OR intervention* OR program* OR procedure*)) 
2 (radio-frequency NEAR (ablati* OR therap* OR treatment* OR intervention* OR program* OR procedure*)) 
3 MeSH DESCRIPTOR Catheter Ablation EXPLODE ALL TREES 
4 #1 OR #2 OR #3 
5 MeSH DESCRIPTOR Spinal Neoplasms EXPLODE ALL TREES 
6 ((neoplasm* OR tumor* OR tumour* OR cancer* OR carcinoma*) NEAR (spine* OR spinal OR vertebra*)) 
7 #5 OR #6 
8 MeSH DESCRIPTOR Neoplasm Metastasis EXPLODE ALL TREES 
9 (metasta*) 
10 #8 OR #9 
11 #7 AND #10 
12 ((spine* or spinal or vertebra*) NEAR metasta*) 
13 #5 OR #6 OR #11 OR #12 
14 #4 AND #13 
Total: 1 Hit 
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Search strategy for Embase 
No. Query results Results Date 
#14 (radiofrequency NEAR/5 (ablati* OR therap* OR treatment* OR intervention* 
OR program* OR procedure*)):ti,ab OR (‘radio-frequency’ NEAR/5 (ablati* OR 
therap* OR treatment* OR intervention* OR program* OR procedure*)):ti,ab 
OR ‘catheter ablation’/exp AND (‘spine tumor’/exp OR (spine* OR spinal OR 
vertebra*) NEAR/5 (neoplasm* OR tumor* OR tumour* OR cancer* OR 
carcinoma*) AND (‘metastasis’/exp OR metasta*) OR (spine* OR spinal OR 
vertebra*) NEAR/5 metasta*) 
170 28 Dec 2016 
#13 ‘spine tumor’/exp OR (spine* OR spinal OR vertebra*) NEAR/5 (neoplasm* OR 
tumor* OR tumour* OR cancer* OR carcinoma*) AND (‘metastasis’/exp OR 
metasta*) OR (spine* OR spinal OR vertebra*) NEAR/5 metasta* 
14,381 28 Dec 2016 
#12 (spine* OR spinal OR vertebra*) NEAR/5 metasta* 10,559 28 Dec 2016 
#11 ‘spine tumor’/exp OR (spine* OR spinal OR vertebra*) NEAR/5 (neoplasm* OR 
tumor* OR tumour* OR cancer* OR carcinoma*) AND (‘metastasis’/exp OR 
metasta*) 
11,186 28 Dec 2016 
#10 ‘metastasis’/exp OR metasta* 682,426 28 Dec 2016 
#9 metasta* 679,081 28 Dec 2016 
#8 ‘metastasis’/exp 494,038 28 Dec 2016 
#7 ‘spine tumor’/exp OR (spine* OR spinal OR vertebra*) NEAR/5 (neoplasm* OR 
tumor* OR tumour* OR cancer* OR carcinoma*) 
33,890 28 Dec 2016 
#6 (spine* OR spinal OR vertebra*) NEAR/5 (neoplasm* OR tumor* OR tumour* 
OR cancer* OR carcinoma*) 
32,084 28 Dec 2016 
#5 ‘spine tumor’/exp 7,604 28 Dec 2016 
#4 (radiofrequency NEAR/5 (ablati* OR therap* OR treatment* OR intervention* 
OR program* OR procedure*)):ti,ab OR (‘radio-frequency’ NEAR/5 (ablati* OR 
therap* OR treatment* OR intervention* OR program* OR procedure*)):ti,ab 
OR ‘catheter ablation’/exp 
44,184 28 Dec 2016 
#3 ‘catheter ablation’/exp 26,304 28 Dec 2016 
#2 (‘radio-frequency’ NEAR/5 (ablati* OR therap* OR treatment* OR 
intervention* OR program* OR procedure*)):ti,ab 
1,688 28 Dec 2016 
#1 (radiofrequency NEAR/5 (ablati* OR therap* OR treatment* OR intervention* 
OR program* OR procedure*)):ti,ab 
25,486 28 Dec 2016 
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Search strategy for Medline via Ovid 
Database: Ovid MEDLINE(R) Epub Ahead of Print <December 27, 2016>, Ovid MEDLINE(R) <1946 to  
December Week 1 2016>, Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations <December 27, 2016>,  
Ovid MEDLINE(R) Daily Update <December 07, 2016> 
Search Date: 28.12.2016 
Search Strategy: 
1 (radiofrequency adj3 (ablati* or therap* or treatment* or intervention* or program* or procedure*)).mp. (17673) 
2 (radio-frequency adj3 (ablati* or therap* or treatment* or intervention* or program* or procedure*)).mp. (1067) 
3 exp Catheter Ablation/(28685) 
4 1 or 2 or 3 (34735) 
5 exp Spinal Neoplasms/(14195) 
6 ((neoplasm* or tumo?r* or cancer* or carcinoma*) adj3 (spine* or spinal or vertebra*)).mp. (27604) 
7 5 or 6 (27604) 
8 exp Neoplasm Metastasis/(198561) 
9 metasta*.mp. (523323) 
10 8 or 9 (530739) 
11 7 and 10 (7392) 
12 ((spine* or spinal or vertebra*) adj5 metasta*).mp. (6194) 
13 11 or 12 (9441) 
14 4 and 13 (81) 
15 remove duplicates from 14 (75) 
 
 
Search strategy for PubMed 
Search Name: RFA for Metastases of the Spine 
Search Date: 29.12.2016 
((radiofrequency ablation OR radiofrequency therapy OR radiofrequency treatment OR radiofrequency intervention 
OR radiofrequency program OR radiofrequency procedure OR RFA OR Catheter Ablation)) AND ((((Spinal Neoplasms 
OR Spinal Tumors OR Spinal Cancer OR Spinal Carcinoma OR Spine Neoplasms OR Spine Tumors OR Spine Cancer OR 
Spine Carcinoma OR Vertebral Neoplasms OR Vertebral Tumors OR Vertebral Cancer OR Vertebral Carcinoma) AND 
(Neoplasm Metastasis[MesH] OR metastasis OR metastases OR metastatic))) OR (Spinal metastasis OR Spinal 
metastases OR Spinal metastatic OR Spine metastasis OR Spine metastases OR Spine metastatic OR Vertebral 
metastasis OR Vertebral metastases OR Vertebral metastatic)) 
Total: 193 Hits 
 
 
  
 
 
 
